CN117794909A - 改进物质特性的免疫调节酰胺衍生物 - Google Patents
改进物质特性的免疫调节酰胺衍生物 Download PDFInfo
- Publication number
- CN117794909A CN117794909A CN202280054582.4A CN202280054582A CN117794909A CN 117794909 A CN117794909 A CN 117794909A CN 202280054582 A CN202280054582 A CN 202280054582A CN 117794909 A CN117794909 A CN 117794909A
- Authority
- CN
- China
- Prior art keywords
- lenalidomide
- pomalidomide
- derivative
- sugar
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002519 immonomodulatory effect Effects 0.000 title description 7
- 150000001408 amides Chemical class 0.000 title description 5
- 230000000704 physical effect Effects 0.000 title description 5
- 229960004942 lenalidomide Drugs 0.000 claims abstract description 148
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims abstract description 101
- 229960000688 pomalidomide Drugs 0.000 claims abstract description 101
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims abstract description 82
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 64
- 235000000346 sugar Nutrition 0.000 claims abstract description 41
- 238000002360 preparation method Methods 0.000 claims abstract description 30
- 239000003889 eye drop Substances 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims description 60
- 239000008194 pharmaceutical composition Substances 0.000 claims description 47
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 40
- 239000004480 active ingredient Substances 0.000 claims description 39
- 208000034578 Multiple myelomas Diseases 0.000 claims description 34
- 206010028980 Neoplasm Diseases 0.000 claims description 33
- 201000011510 cancer Diseases 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
- 208000002780 macular degeneration Diseases 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 230000002491 angiogenic effect Effects 0.000 claims description 16
- 208000014644 Brain disease Diseases 0.000 claims description 14
- 208000027866 inflammatory disease Diseases 0.000 claims description 14
- 238000002347 injection Methods 0.000 claims description 14
- 239000007924 injection Substances 0.000 claims description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 13
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 12
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 12
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 12
- 239000008103 glucose Substances 0.000 claims description 12
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 11
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 8
- 229940097043 glucuronic acid Drugs 0.000 claims description 8
- 125000005543 phthalimide group Chemical group 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 7
- 230000002792 vascular Effects 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 6
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 claims description 5
- 230000033115 angiogenesis Effects 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 4
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 4
- 201000002832 Lewy body dementia Diseases 0.000 claims description 4
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 201000007737 Retinal degeneration Diseases 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- 208000009443 Vascular Malformations Diseases 0.000 claims description 4
- 201000004810 Vascular dementia Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 4
- 208000021921 corneal disease Diseases 0.000 claims description 4
- 201000011190 diabetic macular edema Diseases 0.000 claims description 4
- 206010016629 fibroma Diseases 0.000 claims description 4
- 201000011066 hemangioma Diseases 0.000 claims description 4
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 201000003142 neovascular glaucoma Diseases 0.000 claims description 4
- 230000004258 retinal degeneration Effects 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 230000009529 traumatic brain injury Effects 0.000 claims description 4
- 206010000830 Acute leukaemia Diseases 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 206010010741 Conjunctivitis Diseases 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 206010030113 Oedema Diseases 0.000 claims description 3
- 208000024207 chronic leukemia Diseases 0.000 claims description 3
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 3
- 208000034189 Sclerosis Diseases 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 150000004044 tetrasaccharides Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 44
- -1 thalidomide compound Chemical class 0.000 abstract description 33
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical class O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 abstract description 21
- 229960003433 thalidomide Drugs 0.000 abstract description 21
- 229940124597 therapeutic agent Drugs 0.000 abstract description 16
- 230000001965 increasing effect Effects 0.000 abstract description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 46
- 230000000694 effects Effects 0.000 description 46
- 238000011282 treatment Methods 0.000 description 39
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 38
- 238000000034 method Methods 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 30
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 description 27
- 102000015367 CRBN Human genes 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 230000027455 binding Effects 0.000 description 23
- 230000002265 prevention Effects 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 20
- 239000000546 pharmaceutical excipient Substances 0.000 description 20
- 239000003755 preservative agent Substances 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 108010013958 Ikaros Transcription Factor Proteins 0.000 description 16
- 102000017182 Ikaros Transcription Factor Human genes 0.000 description 16
- 238000000354 decomposition reaction Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 13
- 101000599042 Homo sapiens Zinc finger protein Aiolos Proteins 0.000 description 12
- 102100037798 Zinc finger protein Aiolos Human genes 0.000 description 12
- 239000002775 capsule Substances 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 229920002472 Starch Polymers 0.000 description 11
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 11
- 235000019698 starch Nutrition 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 10
- 239000013543 active substance Substances 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 102000008122 Casein Kinase I Human genes 0.000 description 9
- 108010049812 Casein Kinase I Proteins 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 229940032147 starch Drugs 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 8
- 235000011054 acetic acid Nutrition 0.000 description 8
- 230000001640 apoptogenic effect Effects 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 229920002477 rna polymer Polymers 0.000 description 8
- 229930183167 cerebroside Natural products 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 229930182555 Penicillin Natural products 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
- 229910004298 SiO 2 Inorganic materials 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- 102000040945 Transcription factor Human genes 0.000 description 6
- 108091023040 Transcription factor Proteins 0.000 description 6
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 6
- 235000010443 alginic acid Nutrition 0.000 description 6
- 229920000615 alginic acid Polymers 0.000 description 6
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 6
- 229960004756 ethanol Drugs 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 201000000050 myeloid neoplasm Diseases 0.000 description 6
- 229940049954 penicillin Drugs 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 5
- 229960001467 bortezomib Drugs 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 229940124622 immune-modulator drug Drugs 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 208000032170 Congenital Abnormalities Diseases 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 239000002033 PVDF binder Substances 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 4
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical group C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 4
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 4
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 4
- 239000000783 alginic acid Substances 0.000 description 4
- 229960001126 alginic acid Drugs 0.000 description 4
- 150000004781 alginic acids Chemical class 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 235000010216 calcium carbonate Nutrition 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- 239000008389 polyethoxylated castor oil Substances 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 229940127079 antineoplastic immunimodulatory agent Drugs 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical group O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000003390 teratogenic effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- FZTLLUYFWAOGGB-UHFFFAOYSA-N 1,4-dioxane dioxane Chemical compound C1COCCO1.C1COCCO1 FZTLLUYFWAOGGB-UHFFFAOYSA-N 0.000 description 2
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000005403 Casein Kinases Human genes 0.000 description 2
- 108010031425 Casein Kinases Proteins 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 101800001982 Cholecystokinin Proteins 0.000 description 2
- 102100025841 Cholecystokinin Human genes 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 102100028907 Cullin-4A Human genes 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
- 206010050469 Holt-Oram syndrome Diseases 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 240000003183 Manihot esculenta Species 0.000 description 2
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 2
- 101710085938 Matrix protein Proteins 0.000 description 2
- 101710127721 Membrane protein Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 229940079156 Proteasome inhibitor Drugs 0.000 description 2
- 102100032783 Protein cereblon Human genes 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 2
- 241001135917 Vitellaria paradoxa Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 108091007916 Zinc finger transcription factors Proteins 0.000 description 2
- 102000038627 Zinc finger transcription factors Human genes 0.000 description 2
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- XSIFPSYPOVKYCO-UHFFFAOYSA-N butyl benzoate Chemical compound CCCCOC(=O)C1=CC=CC=C1 XSIFPSYPOVKYCO-UHFFFAOYSA-N 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229960002438 carfilzomib Drugs 0.000 description 2
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 2
- 108010021331 carfilzomib Proteins 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229960002798 cetrimide Drugs 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 229940107137 cholecystokinin Drugs 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 102000022604 damaged DNA binding proteins Human genes 0.000 description 2
- 108091013406 damaged DNA binding proteins Proteins 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- SMVRDGHCVNAOIN-UHFFFAOYSA-L disodium;1-dodecoxydodecane;sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC SMVRDGHCVNAOIN-UHFFFAOYSA-L 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 229920000591 gum Polymers 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940076144 interleukin-10 Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 229960004184 ketamine hydrochloride Drugs 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229940087766 mydriacyl Drugs 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 239000002997 ophthalmic solution Substances 0.000 description 2
- 229940054534 ophthalmic solution Drugs 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 230000004526 pharmaceutical effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229960004838 phosphoric acid Drugs 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 2
- 229940043349 potassium metabisulfite Drugs 0.000 description 2
- 235000010263 potassium metabisulphite Nutrition 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 229940095574 propionic acid Drugs 0.000 description 2
- 239000003207 proteasome inhibitor Substances 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000003156 radioimmunoprecipitation Methods 0.000 description 2
- 229940057910 shea butter Drugs 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 229940001607 sodium bisulfite Drugs 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 229940082004 sodium laurate Drugs 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- XDFGPVSVSMWVQE-UHFFFAOYSA-M sodium;dodecanoic acid;hydrogen sulfate Chemical compound [Na+].OS([O-])(=O)=O.CCCCCCCCCCCC(O)=O XDFGPVSVSMWVQE-UHFFFAOYSA-M 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 235000011078 sorbitan tristearate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 231100000378 teratogenic Toxicity 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 229960004791 tropicamide Drugs 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- WGIMXKDCVCTHGW-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCCO WGIMXKDCVCTHGW-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- LKEGXJXRNBALBV-PMCHYTPCSA-N 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]-N-[4-[[2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetyl]amino]butyl]acetamide Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NCCCCNC(=O)COC(C=1C2=O)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O LKEGXJXRNBALBV-PMCHYTPCSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 1
- DUVVGYBLYHSFMV-YGEZULPYSA-N 4-methyl-n-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]carbamoyl]benzamide Chemical compound C1=CC(C)=CC=C1C(=O)NC(=O)N[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DUVVGYBLYHSFMV-YGEZULPYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229930185605 Bisphenol Natural products 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 244000188595 Brassica sinapistrum Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000005747 Carum carvi Nutrition 0.000 description 1
- 240000000467 Carum carvi Species 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 101150015280 Cel gene Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 240000009226 Corylus americana Species 0.000 description 1
- 235000001543 Corylus americana Nutrition 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 108010088874 Cullin 1 Proteins 0.000 description 1
- 102100039195 Cullin-1 Human genes 0.000 description 1
- 101710159242 Cullin-4A Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000271571 Dromaius novaehollandiae Species 0.000 description 1
- 201000000913 Duane retraction syndrome Diseases 0.000 description 1
- 201000001355 Duane-radial ray syndrome Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000916245 Homo sapiens Cullin-4A Proteins 0.000 description 1
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 description 1
- 101000740178 Homo sapiens Sal-like protein 4 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010051151 Hyperviscosity syndrome Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 244000165082 Lavanda vera Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 241000408747 Lepomis gibbosus Species 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 235000012854 Litsea cubeba Nutrition 0.000 description 1
- 240000002262 Litsea cubeba Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 244000179970 Monarda didyma Species 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 208000031785 Okihiro syndrome Diseases 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 102100037192 Sal-like protein 4 Human genes 0.000 description 1
- 240000000513 Santalum album Species 0.000 description 1
- 235000008632 Santalum album Nutrition 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000040738 Sesamum orientale Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- IYFATESGLOUGBX-NDUCAMMLSA-N [2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-NDUCAMMLSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XGKPLOKHSA-N [2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XGKPLOKHSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 229940009868 aluminum magnesium silicate Drugs 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001446 anti-myeloma Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000010480 babassu oil Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- UDEWPOVQBGFNGE-UHFFFAOYSA-N benzoic acid n-propyl ester Natural products CCCOC(=O)C1=CC=CC=C1 UDEWPOVQBGFNGE-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960003168 bronopol Drugs 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960002562 calcium glucoheptonate Drugs 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 229940078480 calcium levulinate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- FATUQANACHZLRT-XBQZYUPDSA-L calcium;(2r,3r,4s,5r,6r)-2,3,4,5,6,7-hexahydroxyheptanoate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C([O-])=O FATUQANACHZLRT-XBQZYUPDSA-L 0.000 description 1
- ILJIJWPWFKABMW-VAQXQGSJSA-L calcium;(2s,3s,4s,5r)-2,3,4,5-tetrahydroxy-6-oxohexanoate Chemical compound [Ca+2].O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C([O-])=O.O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C([O-])=O ILJIJWPWFKABMW-VAQXQGSJSA-L 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- HUSUHZRVLBSGBO-UHFFFAOYSA-L calcium;dihydrogen phosphate;hydroxide Chemical compound O.[Ca+2].OP([O-])([O-])=O HUSUHZRVLBSGBO-UHFFFAOYSA-L 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 229960005443 chloroxylenol Drugs 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 101150076546 csnk1a1 gene Proteins 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- UMQOSQJMIIITHA-UHFFFAOYSA-N cyclohexylsilane Chemical compound [SiH3]C1CCCCC1 UMQOSQJMIIITHA-UHFFFAOYSA-N 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940111685 dibasic potassium phosphate Drugs 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ONCIQCKBUSMDIK-UHFFFAOYSA-N dihydroxy(dimethoxy)silane Chemical compound CO[Si](O)(O)OC ONCIQCKBUSMDIK-UHFFFAOYSA-N 0.000 description 1
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000000408 embryogenic effect Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229940087559 grape seed Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000029427 heart-hand syndrome Diseases 0.000 description 1
- JQOAQUXIUNVRQW-UHFFFAOYSA-N hexane Chemical compound CCCCCC.CCCCCC JQOAQUXIUNVRQW-UHFFFAOYSA-N 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 229940113174 imidurea Drugs 0.000 description 1
- 230000008975 immunomodulatory function Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 239000008633 juniper tar Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229960000816 magnesium hydroxide Drugs 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- OLXYLDUSSBULGU-UHFFFAOYSA-N methyl pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1 OLXYLDUSSBULGU-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 230000002911 mydriatic effect Effects 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229960004109 potassium acetate Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000010235 potassium benzoate Nutrition 0.000 description 1
- 239000004300 potassium benzoate Substances 0.000 description 1
- 229940103091 potassium benzoate Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 235000013926 potassium gluconate Nutrition 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- 229940096992 potassium oleate Drugs 0.000 description 1
- 229940093916 potassium phosphate Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 1
- 235000019252 potassium sulphite Nutrition 0.000 description 1
- MLICVSDCCDDWMD-KVVVOXFISA-M potassium;(z)-octadec-9-enoate Chemical compound [K+].CCCCCCCC\C=C/CCCCCCCC([O-])=O MLICVSDCCDDWMD-KVVVOXFISA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011865 proteolysis targeting chimera technique Methods 0.000 description 1
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 description 1
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- 235000020236 pumpkin seed Nutrition 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 108010026668 snake venom protein C activator Proteins 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- JZBRFIUYUGTUGG-UHFFFAOYSA-J tetrapotassium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].[K+].[K+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O JZBRFIUYUGTUGG-UHFFFAOYSA-J 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960005066 trisodium edetate Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及将糖(sugar)或糖衍生物引入作为沙利度胺类化合物的来那度胺或泊马度胺中以显著提高水溶性的新型沙利度胺类化合物衍生物,与现有的来那度胺或泊马度胺相比,根据本发明的来那度胺或泊马度胺衍生物的水溶性显著增加,并可配置成注射用或滴眼用制剂,因此,可以在局部给药高浓度的治疗剂,并且可以简单地与其他开发成注射用或滴眼用制剂的治疗剂联合给药。
Description
技术领域
本发明涉及改进物质特性的免疫调节酰胺衍生物,具体而言,涉及将糖(sugar)或糖衍生物引入作为沙利度胺类化合物的来那度胺或泊马度胺中以显著提高水溶性的来那度胺或泊马度胺衍生物。
背景技术
沙利度胺(Thalidomide)为20世纪50年代后期至60年代为预防孕妇孕吐而销售的药物,但随着致畸形性副作用的报道,不仅是孕妇,处于育龄期的人或可能怀孕的人也被禁止复用及处理。然而,随着近来沙利度胺的多发性骨髓瘤治疗效果及其副作用机制被查明,利用沙利度胺类化合物的多发性骨髓瘤治疗剂的研究开发正在积极进行。
多发性骨髓瘤为浆细胞异常分化及增殖而出现的血癌,这种异常浆细胞被称为骨髓瘤细胞(myeloma cell)。骨髓瘤细胞产生肿瘤,溶骨引起疼痛,易骨折,侵入骨髓,降低白细胞、红细胞及血小板数值,增加贫血、感染及出血的风险。不仅如此,骨髓瘤细胞还会产生作为非正常免疫蛋白质的M蛋白质(M protein),因此血液浓度变稠,导致血液高黏滞综合征或肾脏受损。主要多发在黑人、男性、65岁以上高龄人身上,韩国最近发病频率呈逐渐增加的趋势。作为这些多发性骨髓瘤的主要治疗剂,具有硼替佐米、沙利度胺、来那度胺、泊马度胺,作为注射剂的硼替佐米在市场上一直保持增长趋势,口服剂由来那度胺代替了现有的沙利度胺的地位(position),在市场上保持较高的增长势头。
来那度胺作为沙利度胺的新一代药物,具有更强的癌细胞死亡和免疫调节作用,比沙利度胺具有更优异的治疗效果。据悉,在现有治疗中复发或不接受治疗的情况下,当联合使用来那度胺和地塞米松进行治疗时,无病生存时间为13.4个月,整体生存时间为38个月,相当有效。据悉,至于副作用,以往在沙利度胺中出现的末梢神经病症等问题几乎消失,只是骨髓抑制副作用稍微加重,但如果给药白细胞促进因子等,就不会有大问题。
泊马度胺于2013年被美国食品药品监督管理局(FDA)批准为复发难治性多发性骨髓瘤治疗剂,对于接受包括来那度胺和硼替佐米在内的至少2种的常规治疗者,在最终治疗结束后60天内病情仍继续发展时使用。泊马度胺直接抑制血管生成和骨髓瘤细胞生长,但这种双重效果以其在骨髓瘤中的活性为中心,而不是通过其他途径,例如肿瘤坏死因子α(TNFα)抑制。通过增强γ干扰素(IFN-γ)、白细胞介素-2(IL-2)及白细胞介素-10(IL-10)的表达以及抑制白细胞介素-6(IL-6)的表达,泊马度胺表现出抗血管生成和抗骨髓瘤活性。
来那度胺和泊马度胺均由美国新基医药公司(Celgene)开发成口服胶囊制剂,并以1mg至25mg的剂量产品化使用。来那度胺在韩国上市的商品名称为雷利度胺胶囊,泊马度胺的在韩国上市的商品名称为泊马度胺/>胶囊,它们都填充在0号胶囊中,长轴约为2.17cm,因此相当长,体积大。
因此,对于患者,特别是高龄患者,服用时多少回感到不便,同时胶囊和水一同服用时,在吞咽过程中可能会出现因胶囊黏在咽喉或食道而卡住的情况,此时,即使喝大量水也很难脱落,稍有不慎药物破裂时伴随痛苦,根据情况可能会引发炎症,鉴于如上所述的各种问题,试图改善口服制剂的物理性质(韩国公开专利10-2020-0013258号)。
然而,这种现有技术是为了改善来那度胺或泊马度胺作为口服制剂的物理性质,来那度胺或泊马度胺不溶于水,因此很难开发成注射剂,因此,如果这些治疗剂与其他治疗剂(特别是,静脉内给药治疗剂)联合给药时,与静脉内给药的其他治疗剂不同,这些治疗剂是口服给药,因此存在如下问题,即以不同方法给药,因此给药方法繁琐,并且口服给药的情况下,很难在局部以高浓度给药注射剂。
对此,本发明人在维持与来那度胺或泊马度胺等效以上的效果的同时,为了能够用作注射剂、滴眼剂、喷雾、贴剂等各种剂型,努力开发出物理性质改善的新型化合物,结果证实,当将糖或糖衍生物引入来那度胺或泊马度胺的邻苯二甲酰亚胺部分(moiety)中存在的氨基(N H2)时,在维持来那度胺或泊马度胺的药学功效的同时,水溶性显著增加,并且可降低因来那度胺或泊马度胺引起的致畸形性副作用,从而完成了本发明。
发明内容
发明要解决的技术问题
本发明的目的在于提供改进物质特性的免疫调节酰胺衍生物,其具有改进的水溶性,以便可用作注射剂或滴眼剂等。
用于解决技术问题的手段
为了实现如上所述的目的,本发明提供来那度胺或泊马度胺的邻苯二甲酰亚胺部分(moiety)上的氨基(NH2)中结合有糖(sugar)或糖衍生物的来那度胺或泊马度胺衍生物。
本发明的特征在于,所述糖或糖衍生物可为三碳糖、四碳糖、五碳糖或六碳糖或其衍生物。
本发明的特征在于,所述糖或糖衍生物可为葡萄糖(Glucose)、核糖(Ribose)、葡萄糖醛酸(Glucuronic acid)或甘油醛(Glycerin aldehyde)。
本发明的特征在于,所述衍生物可选自由以下式Ⅲ至式XⅣ组成的组中:
[式Ⅲ]
[式Ⅳ]
[式Ⅴ]
[式Ⅵ]
[式Ⅶ]
[式VⅢ]
[式Ⅸ]
[式X]
[式XI]
[式XⅡ]
[式XⅢ]
以及
[式XⅣ]
本发明的特征在于,与来那度胺或泊马度胺相比,所述衍生物的水溶性(watersolubility)可提高50%以上。
本发明还提供包含所述衍生物作为有效成分的用于预防或治疗癌症(cancer)的药物组合物。
本发明还提供预防或治疗癌症(cancer)的方法,该方法包括将所述衍生物施用于需要所述衍生物的个体的步骤。
本发明还提供用于预防或治疗癌症(cancer)的所述衍生物的用途。
本发明还提供用于制备用于预防或治疗癌症(cancer)的药物的所述衍生物的用途。
本发明的特征在于,所述癌症可为血癌或固体癌症。
本发明的特征在于,所述血癌可选自由急性白血病、慢性白血病、多发性骨髓瘤、霍奇金淋巴瘤及非霍奇金淋巴瘤组成的组中。
本发明还提供包含所述衍生物作为有效成分的用于预防或治疗骨髓增生异常综合征的药物组合物。
本发明还提供预防或治疗骨髓增生异常综合征的方法,该方法包括将所述衍生物施用于需要所述衍生物的个体的步骤。
本发明还提供用于预防或治疗骨髓增生异常综合征的所述衍生物的用途。
本发明还提供用于制备用于预防或治疗骨髓增生异常综合征的药物的所述衍生物的用途。
本发明还提供包含所述衍生物作为有效成分的用于预防或治疗炎症疾病的药物组合物。
本发明还提供预防或治疗炎症疾病的方法,该方法包括将所述衍生物施用于需要所述衍生物的个体的步骤。
本发明还提供用于预防或治疗炎症疾病的所述衍生物的用途。
本发明还提供用于制备用于预防或治疗炎症疾病的药物的所述衍生物的用途。
本发明的特征在于,所述炎症疾病可选自由牛皮癣、风湿性关节炎及克罗恩病组成的组中。
本发明还提供包含所述衍生物作为有效成分的用于预防或治疗脑疾病的药物组合物。
本发明还提供预防或治疗脑疾病的方法,该方法包括将所述衍生物施用于需要所述衍生物的个体的步骤。
本发明还提供用于预防或治疗脑疾病的所述衍生物的用途。
本发明还提供用于制备用于预防或治疗脑疾病的药物的所述衍生物的用途。
本发明的特征在于,所述脑疾病可选自由外伤性脑损伤、阿尔茨海默病、帕金森病、亨廷顿病、肌萎缩侧索硬化症、多系统萎缩症、阿尔茨海默性痴呆症、血管性痴呆症、额颞痴呆症、路易体痴呆、缺血性脑卒中、出血性脑卒中及多发性硬化症组成的组中。
本发明还提供包含所述衍生物作为有效成分的血管生成疾病预防或治疗用药物组合物。
本发明还提供预防或治疗血管生成疾病的方法,该方法包括将所述衍生物施用于需要所述衍生物的个体的步骤。
本发明还提供用于预防或治疗血管生成疾病的所述衍生物的用途。
本发明还提供用于制备用于预防或治疗血管生成疾病的药物的所述衍生物的用途。
本发明的特征在于,所述血管生成疾病可选自由角膜移植后血管新生、新生血管性青光眼、糖尿病性视网膜病、黄斑变性、糖尿病性黄斑水肿、新生血管引起的角膜疾病、斑点的变性、翼状片、视网膜变性、晶体后纤维增生症、颗粒性结膜炎、血管瘤、血管纤维瘤、血管畸形、动脉硬化、血管粘连及浮肿性硬化症组成的组中。
本发明还提供包含所述衍生物的注射液制剂。
本发明还提供包含所述衍生物的滴眼液制剂。
发明的效果
根据本发明的来那度胺或泊马度胺衍生物与现有的来那度胺或泊马度胺相比具有如下优点,即,水溶性显著增加,因此可配制成注射用或滴眼用制剂,因此可以在局部给药高浓度的治疗剂,并且可以简单地与开发成其他注射用或滴眼用制剂的治疗剂联合给药。并且,与现有的来那度胺或泊马度胺相比,具有可降低致畸形性副作用的效果。
附图说明
图1示出(A)沙利度胺(B)来那度胺(C)泊马度胺的结构式。
图2a示出核糖-来那度胺(Ribose-Lenalidomide)的化学式.
图2b示出核糖-来那度胺(Ribose-Lenalidomide)的相对于蒸馏水(D.W.)的溶解度。
图2c示出核糖-来那度胺(Ribose-Lenalidomide)的CRBN结合能力。
图2d为在作为人类多发性骨髓瘤细胞系的MM.1S细胞系确认核糖-来那度胺(Ribose-Lenalidomide)的肿瘤细胞凋亡效果的结果。
图2e为在作为人类多发性骨髓瘤细胞系的MM.1S细胞系确认核糖-来那度胺(Ribose-Lenalidomide)的艾奥罗斯(Aiolos)、伊卡洛斯(Ikaros)、酪蛋白激酶1α(CK1α)的分辨率的结果。
图2f为在作为人类胚胎癌Tera-1细胞系的HTB-105细胞系确认核糖-来那度胺(Ribose-Lenalidomide)的人类婆罗双树样基因4(SALL4)分辨率的结果。
图2g为使用人外周血单核细胞系(PBMC细胞系)在信使核糖核酸(mRNA)水平确认核糖-来那度胺(Ribose-Lenalidomide)的炎症抑制效果的结果。
图2h为使用人外周血单核细胞系(PBMC细胞系)在蛋白质水平确认核糖-来那度胺(Ribose-Lenalidomide)的炎症抑制效果的结果。
图2i为使用黄斑变性小鼠模型确认核糖-来那度胺(Ribose-Lenali domide)的由玻璃体内直接给药和眼药水的施用所带来的黄斑变性治疗效果的结果。
图3a示出葡萄糖-来那度胺(Glucose-Lenaldiomide)的化学式。
图3b示出葡萄糖-来那度胺(Glucose-Lenaldiomide)的相对于蒸馏水(D.W.)的溶解度。
图3c示出葡萄糖-来那度胺(Glucose-Lenaldiomide)的CRBN结合能力。
图3d为在作为人类多发性骨髓瘤细胞系的MM.1S细胞系确认葡萄糖-来那度胺(Glucose-Lenaldiomide)的肿瘤细胞凋亡效果的结果。
图3e为在作为人类胚胎癌Tera-1细胞系的HTB-105细胞系确认葡萄糖-来那度胺(Glucose-Lenaldiomide)的人类婆罗双树样基因4(S ALL4)分辨率的结果。
图3f为使用黄斑变性小鼠模型确认葡萄糖-来那度胺(Glucose-Le naldiomide)的由玻璃体内直接给药所带来的黄斑变性治疗效果的结果(*p<0.05vs CNV(+载体(Vehicle)))。
图4a示出核糖-泊马度胺(Ribose-Pomalidomide)的化学式。
图4b示出核糖-泊马度胺(Ribose-Pomalidomide)的相对于蒸馏水(D.W.)的溶解度。
图4c示出核糖-泊马度胺(Ribose-Pomalidomide)的CRBN结合能力。
图4d为在作为人类多发性骨髓瘤细胞系的MM.1S细胞系确认核糖-泊马度胺(Ribose-Pomalidomide)的肿瘤细胞凋亡效果的结果。
图4e为在作为人类胚胎癌Tera-1细胞系的HTB-105细胞系确认核糖-泊马度胺(Ribose-Pomalidomide)的人类婆罗双树样基因4(SA LL4)分辨率的结果。
图5a示出葡萄糖-泊马度胺(Glucose-Pomalidomide)的化学式。
图5b示出葡萄糖-泊马度胺(Glucose-Pomalidomide)的相对于蒸馏水(D.W.)的溶解度。
图5c示出葡萄糖-泊马度胺(Glucose-Pomalidomide)的CRBN结合能力。
图5d为在作为人类多发性骨髓瘤细胞系的MM.1S细胞系确认葡萄糖-泊马度胺(Glucose-Pomalidomide)的肿瘤细胞凋亡效果的结果。
具体实施方式
除非以其他方式定义,否则本文中使用的所有技术术语和科学术语与本发明所属技术领域的普通技术人员通常所理解的含义相同。通常,本文中使用的命名法和以下描述的实验方法是在本技术领域中公知的常规使用的方法。
在本发明中,当将适当的糖或糖衍生物引入作为沙利度胺类化合物的来那度胺或泊马度胺的邻苯二甲酰亚胺部分上存在的氨基时,确认来那度胺或泊马度胺的水溶性显著提高,并保持沙利度胺类化合物的药物效果。
因此,从本发明的一个角度而言,涉及来那度胺或泊马度胺的邻苯二甲酰亚胺部分上的氨基(NH2)中结合有糖(sugar)或糖衍生物的来那度胺或泊马度胺衍生物。
来那度胺被公知为(RS)-3-(4-氨基-1-氧代1,3-二氢-2H-异吲哚-2-基)哌啶-2,6-二酮,并具有以下式(Ⅰ):
泊马度胺被公知为(RS)-4-氨基-2-(2,6-二氧代哌啶-3-基)异吲哚-1,3-二酮,并具有以下式(Ⅱ):
泊马度胺为沙利度胺的邻苯二甲酰亚胺中添加氨基的化合物,来那度胺具有邻苯二甲酰亚胺部分(phthalimide moiety)中不具有羰基的泊马度胺的结构(参见图1)。这两种化合物都被称为免疫调节药物(IMiD),并被报道为具有比沙利度胺更强的免疫调节活性。
来那度胺和泊马度胺分别具有邻苯二甲酰亚胺部分(moiety)和戊二酰亚胺部分(moiety)(参见图1),本发明的特征在于,糖或糖衍生物结合在所述邻苯二甲酰亚胺部分上存在的氨基中。
本发明的特征在于,所述糖或糖衍生物可为三碳糖、四碳糖、五碳糖或六碳糖,或它们中任一个衍生物,但不限定于此。
作为本发明的一些方式,其特征在于,所述糖可为葡萄糖(Glucose)、核糖(Ribose)、葡萄糖醛酸(Glucuronic acid)或甘油醛(Glycerin aldehyde),但不限定于此。
本发明的特征在于,所述衍生物可选自由以下式Ⅲ至式XⅣ组成的组中,但不限定于此:
[式Ⅲ]
[式Ⅳ]
[式Ⅴ]
[式Ⅵ]
[式Ⅶ]
[式VⅢ]
[式Ⅸ]
[式X]
[式XI]
[式XⅡ]
[式XⅢ]
[式XⅣ]
在本发明中,由式Ⅲ表示的衍生物或由式Ⅳ表示的衍生物分别为葡萄糖结合到来那度胺的两种类型。
在本发明中,由式Ⅴ表示的衍生物或由式Ⅵ表示的衍生物为核糖结合到来那度胺的。
在本发明中,由式Ⅶ表示的衍生物或由式VⅢ表示的衍生物为葡萄糖结合到泊马度胺的两种类型。
在本发明中,由式Ⅸ表示的衍生物或由式X表示的衍生物为核糖结合到泊马度胺的两种类型。
另一方面,在本发明中,由式XI表示的衍生物为葡萄糖醛酸结合到来那度胺的,由式XⅡ表示的衍生物为甘油醛结合到来那度胺的,由式XⅢ表示的衍生物为葡萄糖醛酸结合到泊马度胺的,由式XⅣ表示的衍生物为甘油醛结合到泊马度胺的。
本发明的特征在于,与来那度胺或泊马度胺相比,所述衍生物的水溶性(watersolubility)得以改善,优选地,所述水溶性约改善10%以上,优选地,约改善20%以上,更优选地,约改善30%以上,最优选地,约改善50%以上。在一些方式,与来那度胺或泊马度胺相比,根据本发明的衍生物水溶性可改善约100%以上,约200%以上,约300%以上,约400%以上或约500%以上。
另一方面,在本发明中确认到所述来那度胺或泊马度胺衍生物以与来那度胺或泊马度胺相似的结合能力结合到羟脑苷脂(CRBN),从而可以发挥与来那度胺或泊马度胺相似程度的分解羟脑苷脂底物的效果。此外,确认所述来那度胺或泊马度胺衍生物能够以与来那度胺或泊马度胺相似的水平诱导多发性骨髓瘤细胞凋亡。与此同时,在本发明中,关于孕妇服用来那度胺或泊马度胺时在产生胎儿过程中分解人类婆罗双树样基因4(SALL4)而引起的作为副作用的致畸形性,确认到根据本发明的来那度胺或泊马度胺衍生物可以诱导人类婆罗双树样基因4(SALL4)的分解较少,与来那度胺或泊马度胺相比,可减少副作用。
羟脑苷脂为沙利度胺的重要且直接靶标,它与DDB1(受损的DNA结合蛋白质)、库林4A(Cullin-4A,CUL4A)及Roc1(cullin 1调节因子)一同形成E3泛素连接酶复合物(E3ubiquitin ligase complex),该复合物使泛素结合到特定蛋白质,使它们成为蛋白质分解的靶标。当通过核糖核酸干扰(RNAi)使羟脑苷脂敲低时,经确认,在几种多发性骨髓瘤细胞系中,阻断由来那度胺或泊马度胺引起的细胞增殖抑制,据报道,来那度胺或泊马度胺通过戊二酰亚胺部分(glutarimide moiety)结合到羟脑苷脂,并通过分解其底物以发挥抗癌效果。
在最近的研究中确认,沙利度胺及其类似物(来那度胺和泊马度胺;均为免疫调节性药剂;称为IMiDs)为B细胞存活因子,可引起作为转录因子的伊卡洛斯(Ikaros)和艾奥罗斯(Aiolos)的分解,因此可使多发性骨髓瘤的生长停止,同时改变免疫细胞功能。此时,作为锌指转录因子的伊卡洛斯(Ikaros,IKZF1)和艾奥罗斯(Aiolos,IKZF3)由免疫调节药物(IMiDs)选择性地结合到羟脑苷脂。并且,发现免疫调节药物(IMiDs)直接结合到羟脑苷脂上后,激活E3连接酶,导致快速泛素化和伊卡洛斯(Ikaros)及艾奥罗斯(Aiolos)的分解(参见Science,343,305,2014;Science,343,301,2014)。伊卡洛斯(Ikaros)和艾奥罗斯(Aiolos)为B细胞和T细胞分化的转录因子,对多发性骨髓瘤细胞的毒性效果因这两种转录因子的消失,导致B细胞中的IRF4和Myc等转录因子的表达低下以诱导骨髓瘤细胞凋亡。
来那度胺是唯一被批准用于治疗染色体5q缺失(5q-)的骨髓增生异常综合征(myelodysplastic syndrome,MDS)的免疫调节药物(IMiD)。然而,其作用机制尚不清楚,在2015年确认,除伊卡洛斯(Ikaros)和艾奥罗斯(Aiolos)外,酪蛋白激酶α(CK1α)也被确认为来那度胺依赖性羟脑苷脂(CRBN)新底物。5q-MDS细胞传递含有缺失的CSNK1A1基因的染色体区域,因酪蛋白激酶1α(CK1α)的单倍体表达,其表达不足(单倍剂量不足表达(haploinsufficient expression))。在这种5q-MDS细胞中,通过来那度胺的酪蛋白激酶1α(CK1α)的分解导致细胞凋亡。并且,通过来那度胺的酪蛋白激酶1α(CK1α)的分解明显强于通过沙利度胺或泊马度胺的诱导,这一发现表明它取决于通过羟脑苷脂(CRBN)识别的底物配体。
另一方面,2018年两个独立组报告了C2H2锌指转录因子人类婆罗双树样基因4(Spalt Like Transcription Factor 4,SALL4)以作为羟脑苷脂(CRBN)的沙利度胺依赖性新底物(neosubstrate)。首先,Fisc her研究小组通过使用人胚胎干细胞(hESC)的质谱法识别了沙利度胺、来那度胺或泊马度胺处理时减少的底物。人类婆罗双树样基因4(SAL L4)被确认为杜安放射状综合征(Duane Radial Ray综合征)、Okihi ro综合征、心手综合征(Holt-Oram综合征)等遗传性疾病的致病基因,这种综合征与沙利度胺胚胎病变部分重叠。此外,Chamberlain的小组也基于与已知的锌指型底物(zinc finger-typeneosubstrates)之间的结构相似性,独立鉴定了人类婆罗双树样基因4(SALL4),两组均得出人类婆罗双树样基因4(SALL4)是引发沙利度胺类化合物的致畸形性(teratogeniceffect)的底物的结论。
因此,从本发明再一角度而言,涉及包含所述衍生物作为有效成分的用于预防或治疗癌症(cancer)的药物组合物。
从另一角度而言,本发明涉及包括将所述衍生物施用于需要所述衍生物的个体的步骤的预防或治疗癌症(cancer)的方法。
从还一角度而言,本发明涉及用于预防或治疗癌症(cancer)的所述衍生物的用途。
从又一角度而言,本发明涉及用于制备用于预防或治疗癌症(can cer)的药物的所述衍生物的用途。
本发明的特征在于,所述癌症可为血癌或固体癌症,但不限定于此。
本发明的特征在于,所述血癌可为急性白血病、慢性白血病、多发性骨髓瘤、霍奇金淋巴瘤及非霍奇金淋巴瘤,但不限定于此。
从又一角度而言,本发明涉及包含所述衍生物作为有效成分的用于预防或治疗骨髓增生异常综合征的药物组合物。
从另一角度而言,本发明涉及包括将所述衍生物施用于需要所述衍生物的个体的步骤的预防或治疗骨髓增生异常综合征的方法。
从另一角度而言,本发明涉及用于预防或治疗骨髓增生异常综合征的所述衍生物的用途。
从另一角度而言,本发明涉及用于制备用于预防或治疗骨髓增生异常综合征的药物的所述衍生物的用途。
从又一角度而言,本发明涉及包含所述衍生物作为有效成分的用于预防或治疗肿瘤的药物组合物,所述肿瘤包括良性肿瘤和恶性肿瘤。
从另一角度而言,本发明涉及包括将所述衍生物施用于需要所述衍生物的个体的步骤的预防或治疗肿瘤的方法。
从另一角度而言,本发明涉及用于预防或治疗肿瘤的所述衍生物的用途。
从另一角度而言,本发明涉及用于制备用于预防或治疗肿瘤的药物的所述衍生物的用途。
另一方面,在本发明中证明,所述来那度胺或泊马度胺衍生物可以发挥与来那度胺或泊马度胺相似或更好的抗炎效果水平。
因此,从又一角度而言,本发明涉及包含所述衍生物作为有效成分的用于预防或治疗炎症疾病的药物组合物。
从另一角度而言,本发明涉及包括将所述衍生物施用于需要所述衍生物的个体的步骤的预防或治疗炎症疾病的方法。
从另一角度而言,本发明涉及用于预防或治疗炎症疾病的所述衍生物的用途。
从另一角度而言,本发明涉及用于制备用于预防或治疗炎症疾病的药物的所述衍生物的用途。
本发明中的特征在于,所述炎症疾病可选自由牛皮癣、风湿性关节炎及克罗恩病组成的组中,但不限定于此。
从又一角度而言,本发明涉及包含所述衍生物作为有效成分的用于预防或治疗脑疾病的药物组合物。
从另一角度而言,本发明涉及包括将所述衍生物施用于需要所述衍生物的个体的步骤的预防或治疗脑疾病的方法。
从另一角度而言,本发明涉及用于预防或治疗脑疾病的所述衍生物的用途。
从另一角度而言,本发明涉及用于制备用于预防或治疗脑疾病的药物的所述衍生物的用途。
本发明的特征在于,所述脑疾病可选自由外伤性脑损伤、阿尔茨海默病、帕金森病、亨廷顿病、肌萎缩侧索硬化症、多系统萎缩症、阿尔茨海默性痴呆症、血管性痴呆症、额颞痴呆症、路易体痴呆、缺血性脑卒中、出血性脑卒中及多发性硬化症组成的组中,但不限定于此。
不仅如此,在本发明中确认,通过动物实验,根据本发明的来那度胺或泊马度胺衍生物可以发挥出有效治疗血管生成疾病之一的黄斑变性的效果。
因此,从又一角度而言,本发明涉及包含所述衍生物作为有效成分的血管生成疾病预防或治疗用药物组合物。
从另一角度而言,本发明涉及包括将所述衍生物施用于需要所述衍生物的个体的步骤的预防或治疗血管生成疾病的方法。
从另一角度而言,本发明涉及用于预防或治疗血管生成疾病的所述衍生物的用途。
从另一角度而言,本发明涉及用于制备用于预防或治疗血管生成疾病的药物的所述衍生物的用途。
本发明的特征在于,所述血管生成疾病可选自由角膜移植后血管新生、新生血管性青光眼、糖尿病性视网膜病、黄斑变性(例如,渗出性年龄相关性黄斑变性或湿润性老年性黄斑变性)、糖尿病性黄斑水肿、新生血管引起的角膜疾病、斑点的变性、翼状片、视网膜变性、晶体后纤维增生症、颗粒性结膜炎、血管瘤、血管纤维瘤、血管畸形、动脉硬化、血管粘连及浮肿性硬化症组成的组中,但不限定于此。
作为一个优选方式,所述血管生成疾病可为黄斑变性,所述衍生物可用注射器施用于玻璃体内,或以眼药水形式注入眼睛。
根据本发明的来那度胺衍生物或泊马度胺衍生物可分别通过pH变化而切割糖(sugar)或糖衍生物,以成为来那度胺或泊马度胺形式,从而可发挥药学效果。作为一个方式,所述来那度胺衍生物或泊马度胺衍生物制备成约pH7至8的组合物为优选,接着,在注入体内的前阶段改变为pH7以下,例如pH6.5以下,优选地,pH6以下,然后可注入体内。作为另一个方式,所述来那度胺衍生物或泊马度胺衍生物被制备成约pH7至8的组合物注入体内之后,根据体内pH变化(例如,随着胃等器官pH的降低),改变为pH7以下,例如pH6.5以下,优选地,pH6以下,从而糖(sugar)或糖衍生物可以被切割。然而,所述衍生物的药理机制并不限于此。
作为优选方式,本发明包含药物组合物,该药物组合物包含有效量的根据本发明的来那度胺衍生物或泊马度胺衍生物作为有效成分。在一些方式中,所述药物组合物用于治疗血癌(例如,多发性骨髓瘤、非霍奇金淋巴瘤等)固体癌症、骨髓增生异常综合征、炎症疾病(例如,牛皮癣、风湿性关节炎、克罗恩病等)、脑疾病(例如,外伤性脑损伤、阿尔茨海默病、帕金森病、亨廷顿病、肌萎缩侧索硬化症、多系统萎缩症、阿尔茨海默性痴呆症、血管性痴呆症、额颞痴呆症、路易体痴呆、缺血性脑卒中、出血性脑卒中及多发性硬化症等)或血管生成疾病(例如,角膜移植后血管新生、新生血管性青光眼、糖尿病性视网膜病、渗出性年龄相关性黄斑变性、湿润性老年性黄斑变性、糖尿病性黄斑水肿、新生血管引起的角膜疾病、斑点的变性、翼状片、视网膜变性、晶体后纤维增生症、颗粒性结膜炎、血管瘤、血管纤维瘤、血管畸形、动脉硬化、血管粘连以及浮肿性硬化症)。
在本发明中,术语“药物组合物(pharmaceutical composition)”或“药物制剂(pharmaceutical formulation)”是指在本发明的新型化合物中包含特别适合体内或体外诊断或治疗用途的稀释剂或载体等制药上允许的赋形剂的混合物。根据一些实施例,可以根据需要,通过给对象体给药的方法来提供包含本发明的组合物的药物组合物。在一些实施例中,本发明的组合物可对人类进行给药。
在本发明中,“联合给药(combination-administer)”或“共同给药(co-administer)”是指本发明中描述的组合物在施用一种以上的追加疗法(例如,抗癌剂、化疗、炎症疾病、或大脑疾病的治疗)的同时,在之前或之后立即给药。本发明的化合物可单独给药或共同给药于患者。共同给药(coadministration)是指以单独或(一种以上化合物或激动剂)组合的方式同时或连续给药化合物。因此,制剂(preparation)在需要时还可与其他活性物质结合。
本发明中使用的“有效量(effective amount)”或“治疗有效量(therapeutically-effective amount)”是指足以达到有益或期望的结果的化合物或组合物(例如,本发明的化合物或组合物)的量。有效量能够以一种以上的给药、应用或剂量进行给药,并不旨在限于特定制剂或给药途径。
本申请提供的药物组合物的说明原则上涉及用于给人类给药的药物组合物,但普通技术人员应理解这些组合物通常适合给药于所有种类的动物。即,根据本发明的药物组合物还可给需要兽医治疗的动物,例如,家畜(例如狗、猫等)、农场动物(例如牛、羊、猪、马等)以及实验室动物(例如大鼠、小鼠、豚鼠等)等其他哺乳动物进行给药。充分了解为各种动物进行给药的药物组合物的变形,经验丰富的兽医药理学家必要时可以简单地通过常规实验来设计和/或进行这种变形。
本申请中描述的药物组合物可以在药理学领域中所熟知,或者可通过在其后内容中展开的任何方法制备。通常,这种纯化方法包括将活性成分与赋形剂和/或一种以上其他辅助成分相关联的步骤,接着,在必要时或者需要时包括将产物成型和/或包装成所需的单剂量或多剂量单位的步骤。
本发明的药物组合物也能够以单一单位剂量和/或多个单一单位剂量在制备、包装和/或未包装的情况下销售。如本申请中所使用,“单位剂量”为包含预设量的活性成分的药物组合物的个别量。活性成分的量通常等同于施用于对象体的活性成分的剂量和/或此类剂量的便利分割,例如剂量的1/2或1/3。
本发明的药物组合物内的活性成分、制药上允许的赋形剂、以及/或任意添加成分的相对量将根据治疗对象体的同一性、大小、以及/或障碍以及根据给药组合物的途径而变化。例如,组合物可包含0.001%至100%(w/w)活性成分。
如本申请所使用,制药上允许的赋形剂包括任何适合特定的给药形式目的的所有溶剂、分散介质、稀释剂、或其他液体载体、分散液或悬浮助剂、表面活性剂、等渗剂、增稠剂或乳化剂、防腐剂、固体粘合剂、润滑剂等。雷明顿(Remington)的文献[The Science andPractice of Pharmacy,21st Edition,A.R.Gennaro,(Lippincott,Williams&Wilkins,Baltimore,MD,2006]公开了用于制备药物组合物的各种赋形剂及用于制备其的公知技术。对于任意常规载体培养基,除了例如提供任意不期望的生物学效应或以有害方式与药物组合物的任意其他成分相互作用而无法与物质或其衍生物共存之外,其用途均考虑落在本发明的范围之内的用途。制药上允许的赋形剂至少纯至95%、96%、97%、98%、99%或100%。
所述赋形剂已在人类和兽医用途上获得批准。在一些实施例中,赋形剂已被美国食品药品局批准。在一些实施例中,赋形剂为制药级别。在一些实施例中,赋形剂符合美国药典(USP)、欧洲药典(EP)、英国药典、以及/或国际药典(EP)的标准。
在一些实施例中,赋形剂已在人类和兽医用途上获得批准。在一些实施例中,赋形剂已被美国食品药品局批准。在一些实施例中,赋形剂为制药级别。在一些实施例中,赋形剂符合美国药典(USP)、欧洲药典(EP)、英国药典、以及/或国际药典(EP)的标准。
用于药物组合物制备的制药上允许的赋形剂包括但不限于惰性稀释剂、分散剂和/或颗粒剂、表面活性剂和/或乳化剂、崩解剂、粘合剂、防腐剂、缓冲剂、润滑剂以及/或油。
这些赋形剂可以任意包含在本发明的制剂。赋形剂,例如可可脂及栓剂蜡、着色剂、涂层剂、甜味剂、香味剂以及加香剂可以根据制造商的判断存在于组合物中。
示例性稀释剂包括但不限于碳酸钙、碳酸钠、磷酸钙、磷酸二钙、硫酸钙、磷酸氢钙、磷酸钠、乳糖、蔗糖、纤维素、微晶纤维素、高岭土、甘露醇、山梨糖醇、肌醇、氯化钠、干淀粉、玉米淀粉、粉状糖以及它们的组合。
示例性颗粒剂和/或分散剂包括但不限于马铃薯淀粉、玉米淀粉、木薯淀粉、羟基乙酸淀粉钠、粘土、海藻酸、瓜尔豆胶、柑桔渣、琼脂、膨润土、纤维素及木材产物、天然海绵、阳离子-交换树脂、碳酸钙、硅酸盐、碳酸钠、交联聚乙烯基吡咯烷酮(交联聚维酮)、羧甲基淀粉钠(羟基乙酸淀粉钠)、羧甲基纤维素、交联型羧甲基纤维素钠(交联羧甲基纤维素)、甲基纤维素、预糊化淀粉(淀粉1500)、微晶淀粉、水不溶性淀粉、羧甲基纤维素钙、硅酸铝镁(VEEGUM)、硫酸月桂酸钠、季铵化合物以及它们的组合。
示例性表面活性剂和/或乳化剂包括但不限于天然乳化剂(例如刺槐、琼脂、海藻酸、海藻酸钠、黄芪胶、角叉菜属(chondrux)、胆固醇、黄原胶、果胶、明胶、蛋黄、酪蛋白、羊毛脂肪、胆固醇、蜡以及卵磷脂)、胶质粘土(例如膨润土[硅酸铝]及VEEGUM[硅酸铝镁])、长链氨基酸衍生物、高分子醇(例如十八烷醇、十六烷醇、油醇、单硬脂酸三乙酯、乙二醇二硬脂酸、硬脂酸甘油酯、以及丙二醇单硬脂酸酯、聚乙烯醇)、卡波姆(例如羧聚乙烯、聚丙烯酸、丙烯酸聚合物以及聚羧乙烯聚合物)、卡拉胶、纤维素衍生物(例如羧甲基纤维素钠、粉状纤维素、羟甲基纤维素、羟丙基纤维素、羟丙基甲基纤维素、甲基纤维素)、山梨醇酐脂肪酸酯(例如聚氧乙烯失水山梨醇单月桂酸酯[吐温20]、聚氧乙烯山梨醇酐[吐温60]、聚氧乙烯失水山梨醇单油酸酯[吐温80]、失水山梨醇棕榈酸酯[司盘40]、失水山梨醇单硬脂酸酯[司盘60]、山梨醇酐三硬脂酸酯[司盘65]、甘油单油酸酯、山梨糖醇酐单油酸酯[司盘80])、聚氧乙烯酯(例如聚氧乙烯单硬脂酸酯[Myrj45]、聚氧乙烯氢化蓖麻油、聚乙氧基蓖麻油、聚甲醛硬脂酸酯以及羟基硬脂酸酯)、蔗糖脂肪酸酯、聚乙二醇脂肪酸酯(例如克列莫佛(Cremophor))、聚氧乙烯醚(例如聚氧乙烯月桂醚[Brij30])、聚乙烯吡咯烷酮、二甘醇单月桂酸酯、三乙醇胺油酸酯、油酸钠、油酸钾、油酸乙酯、油酸、月桂酸乙酯、硫酸月桂酸钠、丙二醇嵌段聚醚F68、泊洛沙姆188、西曲溴铵、西吡氯铵、苯扎氯铵、多库酯钠以及/或它们的组合。
示例性粘合剂包括但不限于淀粉(例如玉米淀粉及淀粉糊);明胶;糖(例如蔗糖、葡萄糖、右旋葡萄糖、糊精、糖蜜、乳糖、乳糖醇、甘露醇);天然和合成胶(例如刺槐、海藻酸钠、爱尔兰苔藓提取物、潘瓦尔胶(panwar gum)、印度树胶(ghatti gum)、isapol果壳粘液、羧甲基纤维素、甲基纤维素、乙基纤维素、羟乙基纤维素、羟丙基纤维素、羟丙基甲基纤维素、微晶纤维素、乙酸纤维素、聚乙烯吡咯烷酮、硅酸铝镁(VEEGUM)以及落叶松阿拉伯半乳聚糖);藻酸盐;聚环氧乙烷;聚乙二醇;无机钙盐;硅酸;聚甲基丙烯酸酯;蜡;水;醇;及它们的组合。
示例性防腐剂还可包括抗氧化剂、螯合剂、抗微生物保鲜剂、抗真菌保鲜剂、酒精保鲜剂、酸性防腐剂、以及其他保鲜剂。示例性抗氧化剂包括但不限于α生育酚、抗坏血酸、抗坏血酸棕榈酸酯、丁基羟基茴香醚、丁基羟基甲苯、硫代甘油、焦亚硫酸钾、丙酸、没食子酸丙酯、抗坏血酸钠、亚硫酸氢钠、焦亚硫酸钠、以及亚硫酸钠。示例性螯合剂包括乙二胺四乙酸(EDTA)、柠檬酸一水合物、乙二胺四乙酸钠、乙二胺四乙酸钾、依地酸、富马酸、苹果酸、磷酸、依地酸钠、酒石酸以及依地酸三钠。示例性抗微生物保鲜剂包括但不限于苯扎氯铵、卞索氯铵、苯甲醇、溴硝丙二醇、溴棕三甲铵、西吡氯铵、氯己定、氯丁醇、氯甲酚、氯二甲苯酚、甲酚、乙醇、甘油、氨己嘧啶、咪脲、苯酚、苯氧乙醇、苯乙醇、硝酸苯汞(phenylmercuricnitrate)、丙二醇以及硫柳汞。示例性抗真菌保鲜剂包括但不限于尼泊金丁酯、尼泊金甲酯、尼泊金乙酯、尼泊金丙酯、苯甲酸、羟基苯甲酸、苯甲酸钾、山梨酸钾、苯甲酸钠、丙酸钠以及山梨酸。示例性酒精保鲜剂包括但不限于乙醇、聚乙二醇、苯酚、酚类化合物、双酚、氯丁醇、羟基苯甲酸以及苯乙醇。示例性酸性防腐剂包括但不限于维生素A、维生素C、维生素E、β-胡萝卜素、柠檬酸、乙酸、脱氢乙酸、抗坏血酸、山梨酸以及植酸。其他防腐剂包括但不限于生育酚、醋酸生育酚、甲磺酸得立肟、溴棕三甲铵、丁基羟基茴香醚(BHA)、丁基羟基甲苯(BHT)、乙二胺、硫酸月桂酸钠(SLS)、十二烷基醚硫酸钠(SLES)、亚硫酸氢钠、焦亚硫酸钠、亚硫酸钾、焦亚硫酸钾、GLYDANT PLUS、PHENONIP(防腐剂商品名)、尼泊金甲酯、低摩尔115、双咪唑烷基脲(Germaben II)、尼奥纶、纸箱以及EUKSIL。在特定实施例中,防腐剂为抗氧化剂。在其他实施例中,防腐剂为螯合剂。
示例性缓冲剂包括但不限于柠檬酸盐缓冲溶液、乙酸盐缓冲溶液、磷酸盐缓冲溶液、氯化铵、碳酸钙、氯化钙、柠檬酸钙、葡乳醛酸钙、葡庚糖酸钙、葡萄糖酸钙、D-葡萄糖酸、甘油磷酸钙、乳酸钙、丙酸、乙酰丙酸钙、戊酸、二碱式磷酸钙、磷酸、三碱式磷酸钙、磷酸氢氧化钙、乙酸钾、氯化钾、葡萄糖酸钾、钾混合物、二碱式磷酸钾、一碱式磷酸钾、磷酸钾混合物、乙酸钠、碳酸氢钠、氯化钠、柠檬酸钠、乳酸钠、二碱式磷酸钠、一碱式磷酸钠、磷酸钠混合物、氨丁三醇、氢氧化镁、氢氧化铝、海藻酸、无热源水、等渗盐水、复方氯化钠(Ringer's)溶液、乙醇以及它们的组合。
示例性润滑剂包括但不限于硬脂酸镁、硬脂酸钙、硬脂酸、二氧化硅、滑石、麦芽、甘油二十二烷酸酯、氢化植物油、聚乙二醇、苯甲酸钠、乙酸钠、氯化钠、亮氨酸、十二烷基硫酸镁、硫酸月桂酸钠以及它们的组合。
示例性油包括但不限于扁桃仁、杏核油、牛油果、巴巴苏油椰、香柠檬精油、黑加仑籽、玻璃苣、杜松焦油、甘菊、油菜、葛缕子干籽、棕榈蜡、蓖麻、桂皮、可可脂、椰子、鱼肝油、咖啡、玉米、棉种、鸸鹋、桉树、月见草、鱼、亚麻籽、香叶醇、南瓜、葡萄种子、榛子、海索草、肉豆蔻酸异丙酯、霍霍巴油、夏威夷果、醒目熏衣草、熏衣草、柠檬、山苍子、澳洲坚果、锦葵、芒果种子、白池花籽、皮草、肉豆蔻、橄榄、橙连鳍鲑(Orange Roughy)、棕榈、棕榈仁、桃仁、花生、罂粟籽、南瓜籽、油菜籽、米糠、迷迭香、红花、檀香、山茶花(sasqua na)、香草、沙棘、芝麻、乳木果油、硅、大豆、向日葵、茶树、大蓟、杉树、香根草、核桃以及小麦胚芽油。示例性油包括但不限于硬脂酸丁酯、辛酸甘油三酯、癸酸甘油三酯、环己基硅烷、癸二酸二乙酯、二甲基硅酸360、肉豆蔻酸异丙酯、矿物质油、辛基十二醇、油醇、硅油以及它们的组合。
用于口服及肠外给药的液体给药形式包括但不限于制药上允许的乳剂、微乳剂、溶液、悬浮液、糖浆及酏剂。除活性成分外,液体给药形式可包括本技术领域中共同施用的惰性稀释剂,例如水或其他溶剂、增溶剂及乳化剂,例如乙醇、异丙醇、碳酸乙酯、乙酸乙酯、苯甲醇、苯甲酸苄酯、丙二醇、1,3-丁二醇、二甲酰胺、油(特别是棉籽、花生、玉米、芽、橄榄、蓖麻油以及芝麻油)、甘油、四氢糠醇、山梨糖醇的聚乙二醇及脂肪酸酯以及它们的混合物。除惰性稀释剂外,口服组合物可包括助剂,例如润湿剂、乳化剂及悬浮剂、甜味剂、香味剂以及加香剂。用于肠外给药的特定实施例中,本发明的新型化合物与增溶剂,例如克列莫佛(Cremophor)、醇、油、改性油、二醇、聚山梨酸盐、环糊精、聚合物以及它们的组合混合。
根据本发明的来那度胺衍生物或泊马度胺衍生物与作为其母体的与来那度胺或泊马度胺相比,水溶性显著提高,作为一种方式,可以用作注射液制剂。
因此,从又一角度而言,本发明涉及包含所述衍生物的注射液制剂。
在本发明中,所谓所述“注射液制剂”的术语可与“注射用剂型”、“注射剂”或“可注射制剂”混合使用。
可注射制剂,例如,无菌可注射水性或油性悬浮液可以使用分散剂或润湿剂及悬浮剂按照公知技术领域配制。无菌可注射制剂还可以非毒性肠外允许的稀释剂或溶剂,例如,1,3-丁二醇内溶液中的无菌可注射溶液、悬浮液或乳剂。在允许的载体及溶剂中可采用的是水、复方氯化钠(Ringer's)溶液、U.S.P.和等渗氯化钠溶液。此外,通常采用无菌、固定油以作为溶剂或悬浮介质。为此,可采用包含合成单-或双甘油酯的任意无刺激固定油。并且,脂肪酸,例如油酸用于注射剂的制备。
可注射制剂可以通过过滤进行灭菌,例如通过带菌过滤器过滤,或者使用前使其包含灭菌剂以进行灭菌,该灭菌剂为可溶解或分散在无菌水或其他灭菌可注射培养基中的无菌固体组合物的形式。
并且,根据本发明的来那度胺衍生物或泊马度胺衍生物与作为其母体的与来那度胺或泊马度胺相比,水溶性显著提高,作为一个方式,可用作滴眼液制剂。
因此,从又一角度而言,本发明涉及包含所述衍生物的滴眼液制剂。
在本发明中,所谓所述“滴眼液制剂”的术语可与“滴眼用剂型”、“滴眼剂”、“眼药剂”、“眼药剂型”或“眼药”混合使用。
另一方面,为了延长药物的效果,通常,优选地,使药物缓慢地从皮下或肌肉内注射吸收。这是通过使用具有低水溶解度的结晶或无定形物质的液体悬浮液来实现。如此,药物的吸收率最终取决于溶解率,该溶解率可取决于结晶大小及结晶形态。作为替代方式,肠外给药药物的延缓吸收通过将药物溶解或悬浮在油载体中来实现。
用于口服给药的固体给药形式包括胶囊、片剂、丸剂、粉剂以及颗粒剂。在这种固体给药形式中,活性成分与以下物质混合:一种以上惰性制药上允许的赋形剂或载体,例如柠檬酸钠或磷酸二钙,和/或a)填充剂或增重剂,例如淀粉、乳糖、蔗糖、葡萄糖、甘露醇以及硅酸,b)粘合剂,例如,羧甲基纤维素、藻酸盐、明胶、聚乙烯吡咯烷酮、蔗糖以及刺槐,c)含湿剂,例如甘油,d)崩解剂,例如琼脂、碳酸钙、土豆或木薯淀粉、海藻酸、特定硅酸盐以及碳酸钠,e)溶解延缓剂,例如石蜡,f)吸收促进剂,例如季铵化合物,g)润湿剂,例如,十六烷醇及甘油单硬脂酸,h)吸收剂,例如高岭土及膨润土粘土,以及i)润滑剂,例如滑石、硬脂酸钙、硬脂酸镁、固体聚乙二醇、硫酸月桂酸钠以及它们的混合物。
对于胶囊,片剂和丸剂的给药形式可包含缓冲剂。相似类型的固体组合物也可以在软质及硬质填充的明胶胶囊中用作填充剂,其中软质及硬质填充的明胶胶囊中使用乳糖或乳糖以及高分子量聚乙二醇等作为赋形剂。片剂、糖衣片、胶囊、丸剂以及颗粒剂的固体给药形式可以与涂层及壳体,例如肠溶涂层及制药调剂领域公知的其他涂层一同制备。这些可任意包含不透明剂,也可以是仅释放活性成分,或者优先释放肠道特定部分,任意延缓方式释放的组合物。可使用的包埋组合物的示例包括聚合物材料和蜡。相似类型的固体组合物也可以在软质及硬质填充的明胶胶囊中用作填充剂,其中软质及硬质填充的明胶胶囊中使用乳糖或乳糖以及高分子量聚乙二醇等作为赋形剂。
活性成分可以与上述的一种以上赋形剂一同进行微胶囊化的形式。片剂、糖衣片、胶囊、丸剂以及颗粒剂的固体给药形式可与涂层及壳体,例如肠溶涂层、释放控制涂层及制药调剂领域中公知的其他涂层一同制备。在这种固体给药形式中,活性成分可以与一种以上惰性稀释剂,例如蔗糖、乳糖或淀粉混合。这种给药形式可包含额外物质,例如,片剂润滑剂及其他片剂助剂,例如硬脂酸镁及微晶纤维素,而不是如常规实施例中的氟化稀释剂。对于胶囊,片剂和丸剂的给药形式可包含缓冲剂。这些可任意包含不透明剂,也可以是仅释放活性成分,或者优先释放肠道特定部分,任意地延缓方式释放的组合物。可使用的包埋组合物的示例包括聚合物材料和蜡。
本发明的新型化合物或包含该化合物的药物组合物的用于局部给药和/或经皮给药的给药形式可包括软膏、糊、霜剂、乳剂、凝胶、粉剂、溶液、喷雾、吸入剂和/或贴剂。通常,活性成分在无菌障碍下与制药上允许的载体和/或任意所需的防腐剂和/或可能需要的缓冲剂混合。另外,本发明通常考虑使用经皮贴剂,该经皮贴剂的额外优点在于控制活性成分传递到身体。这种给药形式可通过例如将活性成分熔化和/或分散在适当的培养基中来制备。作为替代方式或附加方式,可以提供比率控制膜和/或将活性成分分散在聚合物基质和/或凝胶中以控制比率。
用于局部给药的制剂包括但不限于液体和/或半液体制剂,例如涂抹剂、乳剂、水包油和/或油包水乳剂,例如霜剂、软膏/或糊、以及/或溶液和/或悬浮液。活性成分的浓缩可能与溶剂内活性成分的溶解度限制一样高,但可局部给药的制剂可包含例如约1%至约10%(w/w)活性成分。用于局部给药的制剂还可包含本申请中描述的一种以上附加成分。
例如,用于局部给药的制剂可制备成施用于眼部(eye)的本技术领域中公知的给药形式的剂型。
本申请中描述的本发明的新型化合物或包含该化合物的药物组合物制备成给药单位形式,以进行典型的简单给药及均匀给药。然而,可以理解的是,本发明的组合物的总日用量将在合理的医学判断范围内由责任医师来确定。对任意特定对象体的特定治疗有效剂量水平取决于包括疾病、障碍、或治疗中的障碍及障碍的严重程度的各种因子;所采用的特定活性成分的活性;所采用的特定组合物;对象体的年龄、体重、整体健康、性别及日常饮食;所采用的特定活性成分的给药时间、给药途径以及排泄率;疗程;与所采用的特定活性成分组合或同时使用的药物;以及医疗领域中公知的因子等。
本发明的新型化合物、其盐、或其药物组合物还可通过任意途径给药。在一些实施例中,新型化合物、其盐、或其药物组合物通过包括口服、静脉内、肌肉内、动脉内、髓内、髓腔内、皮下、脑室内、经皮、皮内、直肠、阴道、腹腔内、局部(粉剂、软膏、霜剂以及/或液滴)、粘膜、鼻子、口腔、经肠、舌下;气管滴注,支气管滴注以及/或吸入;和/或口服喷雾,鼻腔喷雾以及/或气溶胶的各种途径来进行给药。具体考虑的途径是渗透静脉内注射、通过血液和/或淋巴供应的局部给药、以及/或患处的直接给药。通常,给药的最合适的途径取决于激动剂的特性(例如,胃肠道环境中的稳定性)、以及包括对象体的障碍(例如对象体是否能够忍受口服给药)的各种因子。
在特定实施例中,本发明的新型化合物、其盐、或其药物组合物能够以足以每天1次以上递送对象体体重的约0.001mg/kg至约100mg/k g、约0.01mg/kg至约50mg/kg、约0.1mg/kg至约40mg/kg、约0.5mg/kg至约30mg/kg、约0.01mg/kg至约10mg/kg、约0.1mg/kg至约10mg/kg、或约1mg/kg至约25mg/kg的给药水平进行给药,以便可获得所期望的治疗效果。目标剂量也可为每日3次、每日2次、每天,每两天、每三天、每周、每两周、每三周、或每四周进行递送。在特定实施方式中,目标剂量可通过多次给药(例如2、3、4、5、6、7、8、9、10、11、12、13、14次以上的给药)来递送。
可理解的是,本申请中描述的剂量范围提供针对提供给成人的药物组合物的给药的指导。例如,给少儿或青少年给药的量可由专业医师或本技术领域的技术人员来确定,可少于或等于给成人的给药量。实现有效量所需的根据本发明的肽的准确量可随着例如对象体的种类、年龄以及整体障碍、副作用或障碍的严重程度、特性化合物的同一性,给药方式等,对象体有可能不同。
可理解的是,本发明的新型化合物及药物组合物可用作组合疗法。用于组合疗法的治疗的特定组合(治疗剂或步骤)将考虑到所要达到的目标治疗效果及目标治疗剂和/或步骤的适用性。
本发明的药物组合物可单独给药或与一种以上的治疗活性剂组合给药。对于“组合”,以下递送方法虽属于本发明的范围,但并不意图暗示激动剂必须在同一时间给药和/或配制成制剂以一同递送。组合物可以与一种以上的其他目标治疗剂或医疗步骤一同、更早、或更晚给药。通常,各个激动剂将按照以对激动剂规定的剂量和/或时间安排来进行给药。另外,本发明与在体内改善其的身体利用率,减少和/或修改其的代谢,抑制其分泌,以及/或能够修改其分布的激动剂组合来递送本发明的药物组合物。该组合中使用的本发明的新型化合物及治疗活性剂可作为单一组合物一同给药,或者以不同的组合物单独给药。
用于组合疗法的特定组合将考虑所要达到的目标治疗效果和/或包含本发明的肽的步骤和/或治疗活性剂的实用性。可以理解的是,使用的组合可对于相同的障碍实现目标效果(例如,本发明的新型化合物可与用于治疗相同障碍的其他治疗活性剂(例如,第二治疗剂)并用来进行给药)以及/或这些将实现不同的(例如,任意副作用控制)。
本申请中使用的“治疗活性剂”是指用于治疗、预防、延缓、还原或改善障碍的药物所使用的任意物质,额用于预防性治疗及治愈性治疗的物质。
在一些实施方式中,用于联合给药的其他治疗活性剂用于治疗多发性骨髓瘤。在一些方式中,所述其他治疗活性剂可以选自由蛋白酶体抑制剂(proteasome inhibitor)和/或免疫调节药物(immune modifyin g drugs)。在本发明中,所述其他治疗活性剂可选自由地塞米松(dex amethasone)、硼替佐米(bortezomib)、卡非佐米(carfilzomib)、美法仑(melphalan)、阿霉素(doxorubicin)及环磷酰胺(cyclophospha mide)组成的组中,但不限定于此。
在一些实施例中,本发明的药物组合物可以与治疗、减轻,改善、缓解一种以上的症状或特征、对于延缓其开始、抑制其进展、降低其严重程度以及/或降低其发生率有用的任意治疗活性剂或步骤(例如,手术、放射线疗法)组合给药。
在各种方式中,本发明提供一种在患有多发性骨髓瘤的对象体上治疗多发性骨髓瘤的试剂盒。在一些方式中,所述试剂盒可包括i)用于向患有多发性骨髓瘤的对象体施用根据本发明的来那度胺衍生物或泊马度胺衍生物组合物或药物组合物的说明书(instruction)、以及ii)根据本发明的来那度胺衍生物或泊马度胺衍生物组合物或药物组合物。在一些方式中,所述试剂盒可包括至少一种单位给药形式(unit dosag e form),该单位给药形式包含有效治疗对象体内的多发性骨髓瘤的如本申请中所记载的剂量的来那度胺衍生物或泊马度胺衍生物或药物组合物。在一些方式中,所述对象体为人类患者。
在一些方式中,所述试剂盒还包括选自包括无菌注射器、无菌针、无菌IV袋、注入泵或它们的任意组合的组中的一种以上。
本申请中使用的术语“约(about)”可以解释为大约、大致或一定程度的含义。术语“约”与数字范围一同使用时,应将指定数字值的上下扩展界限,修改解释相应范围。通常,术语“约”在本申请中用于用于修改由方差为10%规定值的上下数值。
“个体(individual)”、“患者(patient)”及“对象体(subjec t)”相互交换使用,包括哺乳类,例如小鼠、大鼠、其他啮齿动物、兔子、狗、猫、猪、牛、羊、马或包括人类在内的灵长类动物的任意动物。
实施例
以下,通过实施例进一步详细描述本发明。这些实施例仅用于示例性说明本发明,本发明的范围不被解释为受这些实施例的限制,这对于本技术领域所属的普通技术人员而言是显而易见的。
实施例1.核糖-来那度胺(Ribose-Lenalidomide)
1-1.合成
将100mg(0.386mmol)的来那度胺溶解在1.00mL的二甲基甲酰胺(DMF)和1.00mL的乙醇(EtOH)中的溶液和将290mg(1.93mmol)核糖(Ribose)溶解在0.500mL的水和53.0μL(0.926mmol)乙酸(AcOH)中的溶液进行混合。将混合物在60℃下搅拌过夜并减压浓缩。将残留物经二氧化硅(SiO2)(二氯甲烷(DCM):甲醇(MeOH)=9:1~8:1)柱层析纯化后C18-SiO2(水100%~甲醇(MeOH):H2O=3:1)柱层析纯化,以合成了核糖-来那度胺(类型1,图2a,式V)。
1-2.水溶性
分别称取来那度胺(Combi-Block,Inc.San Diego,CA,USA)和核糖-来那度胺3mg,分别放入1.5mL的埃彭道夫管(Eppendorf Tubes)中,加入0.03mL水之后涡旋(Vortexing)1分钟,接着,以15000rpm离心分离1分钟,沉淀了未溶解的化合物。当观察到沉淀的化合物时,加入0.03mL水重复上述过程。
如美国药典(United States Pharmacopeia 23,以下简称为USP23)中所定义,溶解度由表1确定。
表1
其结果,如图2b所示,确认核糖-来那度胺(类型1)在水中的溶解度为100mg/ml浓度以上(基于USP 23的易溶解的(Freely soluble)),反之,来那度胺完全不溶于水。
1-3.羟脑苷脂(CRBN)结合能力
已知来那度胺等免疫调节酰胺类化合物通过与羟脑苷脂(Cereblo n,CRBN)蛋白结合以发挥作用。因此,比较了核糖-来那度胺的羟脑苷脂(Cereblon,CRBN)蛋白之间的结合能力与作为其母体的来那度胺(Combi-Block,Inc.San Diego,CA,USA)的羟脑苷脂(Cereblo n,CRBN)蛋白之间的结合能力。
为此,使用基于荧光的α检测试剂盒(Alpha assay kit)(PROTAC Optimizationkit for BET Bromodomain-Cereblon Binding(BPS Bioscience,#79770)),按照制造商的说明,对CRBN和dBET1的结合,评价了来那度胺和核糖-来那度胺的竞争性抑制能力。在实验中,使用了AlphaLISA anti-FLAG acceptor beads,5mg/ml(PerkinElmer#AL112C),AlphaGlutathione donor beads,5mg/ml(PerkinElmer#6765300),Optiplate 384(PerkinElmer#6007290),L-Glutathione reduced(G4251,Sigma-Aldrich)。
其结果,如图2c所示,与来那度胺相比,核糖-来那度胺(类型1)显示出改善的与羟脑苷脂(Cereblon,CRBN)蛋白之间的结合能力。
1-4.肿瘤细胞凋亡效果
来那度胺是多发性骨髓瘤患者移植自体干细胞后作为维持疗法得到美国食品药品监督管理局(FDA)批准的治疗剂,还试图确认核糖-来那度胺是否也发挥多发性骨髓瘤细胞凋亡效果。
为此,使用作为人类多发性骨髓瘤细胞系的MM.1S(CRL-2974),其购自美国菌种保藏中心(American Type Culture Collection,ATCC,位于美国弗吉尼亚州马纳萨斯(Manassas,VA,USA)),使用补充有10%胎牛血清(康宁(Corning)公司,位于美国马里兰州(MD,USA))、100U/ml青霉素(penicillin)(康宁(Corning)公司,位于美国马里兰州(MD,USA))、以及100μg/ml链霉素(streptomycin)(康宁(Corning)公司,位于美国马里兰州(MD,USA))的RPMI1640培养基(康宁(Corning)公司,位于美国马里兰州(MD,USA)),在37℃的5%CO2培养箱中培养了24小时。以1×104细胞/孔(cells/well)将细胞分装于96孔板中,培养24小时后,将溶解在二甲基亚砜(DMSO)或蒸馏水(D.W.)中的核糖-来那度胺分别处理0、0.005、0.014、0.041、0.123、0.37、1.111、3.333、10μM,再进一步培养3天后,使用胆囊收缩素(C CK)测定试剂盒(日本同仁化学研究所(Dojindo,Japan)),按照制造商说明进行了分析。
其结果,如图2d所示,确认将核糖-来那度胺(类型1)溶解在二甲基亚砜(DMSO)或蒸馏水(D.W.)中的情况下,均显示出使作为人类多发性骨髓瘤细胞系的MM.1S凋亡的效果。
1-5.艾奥罗斯(Aiolos)、伊卡洛斯(Ikaros)、酪蛋白激酶1α(CK1α)分解效果
已知的是,沙利度胺类化合物与作为E3连接酶的羟脑苷脂(Cer eblon,CRBN)结合,作为其底物,通过分解作为转录因子的艾奥罗斯(Aiolos)和伊卡洛斯(Ikaros)以调节免疫细胞的功能。因此,为了确认是否对核糖-来那度胺仍然保持免疫调节功能,将艾奥罗斯(Aiolos)及伊卡洛斯(Ikaros)分解效果与作为其母体的来那度胺进行了比较。
并且,被公知为羟脑苷脂(Cereblon,CRBN)的另一底物的酪蛋白激酶1α(CK1α)在多发性骨髓瘤中使PI3K/AKT、JAK/STAT及NF-κB等致癌级联持续存在,并促进有助于应对各种有害作用的压力相关信号。对此,试图确认核糖-来那度胺是否能够类似于来那度胺而分解酪蛋白激酶1α(CK1α)以发挥多发性骨髓瘤治疗效果。
为此,使用作为人类多发性骨髓瘤细胞系的MM.1S(CRL-2974),其购自美国菌种保藏中心(American Type Culture Collection,ATCC,位于美国弗吉尼亚州马纳萨斯(Manassas,VA,USA)),使用补充有10%胎牛血清(康宁(Corning)公司,位于美国马里兰州(MD,USA))、100U/ml青霉素(penicillin)(康宁(Corning)公司,位于美国马里兰州(MD,USA))、以及100μg/ml链霉素(streptomycin)(康宁(C orning)公司,位于美国马里兰州(MD,USA))的杜尔贝科改良伊格尔培养基(DMEM)(康宁(Corning)公司,位于美国马里兰州(MD,USA)),在37℃的5%CO2培养箱中培养。
分装细胞并培养24小时后,将每个化合物处理1μM、10μM,再进一步培养24小时。细胞中加入包含蛋白酶抑制剂混合液(protease inhibitor cocktail)(美国赛默飞世尔科技公司(Thermo Fisher Scientific))的放射免疫沉淀法缓冲液(RIPA buffer)并进行破碎,在4℃下,以14000rpm离心分离15分钟以获得了细胞提取液。加载(loading)等量细胞提取液,使用十二烷基硫酸钠聚丙烯酰胺凝胶电泳(SDS-PAGE)进行分离,并转移到聚偏二氟乙烯(PVDF)膜。使用脱脂牛奶(skim milk)封闭转移蛋白质的膜,在4℃下用一抗孵育过夜(o/n)后,在4℃下用辣根过氧化物酶(HRP)标记的二抗孵育1小时。在每个步骤之间用TBS-T洗涤3次。应用化学发光(chemoluminescence)试剂(美国赛默飞世尔科技公司(ThermoFisher Scientific))进行检测,使用Chemidoc(iBright CL1000,Invitrogen,CA,USA)进行了确认。作为使用的一抗,艾奥罗斯(Aiolos)(#15103)、伊卡洛斯(Ikaros)(#9034)、GAPDH(#2118S)、β-肌动蛋白(β-actin)(#3700S)抗体购自Cell signaling technology(Danvers,MA,USA),酪蛋白激酶1α(CK1α)(PA5-17536)抗体购自Invitrogen(Waltham,Massachusetts USA)。
其结果,如图2e所示,确认核糖-来那度胺(类型1)的艾奥罗斯(Aiolos)、伊卡洛斯(Ikaros)、酪蛋白激酶1α(CK1α)分解效果与来那度胺几乎相当,不同溶剂对核糖-来那度胺的艾奥罗斯(Aiolos)、伊卡洛斯(Ikaros)、酪蛋白激酶1α(CK1α)分解效果无差异。
1-6.人类婆罗双树样基因4(SALL4)分解效果
据报道,羟脑苷脂(Cereblon,CRBN)结合治疗剂可引发严重的先天性畸形,例如前肢缩短或断肢症,这与人类婆罗双树样基因4(SALL4)的分解密切相关。对此,将核糖-来那度胺的人类婆罗双树样基因4(SALL4)分解效果与来那度胺进行比较。
为此,使用人类胚胎癌Tera-1细胞系(HTB-105),其购自(American Type CultureCollection,ATCC,位于美国弗吉尼亚州马纳萨斯(Manassas,VA,USA)),使用补充有10%胎牛血清(康宁(Corning)公司,位于美国马里兰州(MD,USA))、100U/ml青霉素(penicillin)(康宁(Corning)公司,位于美国马里兰州(MD,USA))、以及100μg/ml链霉素(streptomycin)(康宁(Corning)公司,位于美国马里兰州(MD,USA))的杜尔贝科改良伊格尔培养基(DMEM)培养基(康宁(Corning)公司,位于美国马里兰州(MD,USA)),在37℃的5%CO2培养箱中培养。
分装细胞并培养24小时后,分别溶解在二甲基亚砜(DMSO)中的来那度胺、溶解在二甲基亚砜(DMSO)或水中的核糖-来那度胺分别处理1或10μM,进一步培养了24小时。细胞中加入包含蛋白酶抑制剂混合液(protease inhibitor cocktail)(美国赛默飞世尔科技公司(Thermo Fisher Scientific))的放射免疫沉淀法缓冲液(RIPA buffer)并进行破碎,在4℃下,以14000rpm离心分离15分钟以获得了细胞提取液。加载(loading)等量细胞提取液,使用十二烷基硫酸钠聚丙烯酰胺凝胶电泳(SDS-PAGE)进行分离,并转移到聚偏二氟乙烯(PVDF)膜。使用脱脂牛奶(skim milk)封闭转移蛋白质的膜,在4℃下用一抗孵育过夜(o/n)后,在4℃下用辣根过氧化物酶(HRP)标记的二抗孵育1小时。在每个步骤之间用TBS-T洗涤3次。应用化学发光(chemoluminescence)试剂(美国赛默飞世尔科技公司(ThermoFisher Scientific))进行检测,使用Chemidoc(iBright CL1000,Invitrogen,CA,USA)进行了确认。作为使用的一抗,人类婆罗双树样基因4(SALL4)(#5850)和GAPDH(#2118S)抗体购自Cell signaling technology(Danvers,MA,USA)。
其结果,如图2f所示,可知,核糖-来那度胺(类型1)与来那度胺相比,显示人类婆罗双树样基因4(SALL4)分解效果得以抑制,核糖-来那度胺与来那度胺相比可以改善致畸形性副作用。
1-7.炎症抑制效果
试图将核糖-来那度胺的炎症抑制效果与来那度胺进行比较。
为此,使用作为人外周血单核细胞系的PBMC,其购自Stemexpress(2.5million,PBMNC025C,#1909040034),使用填充有10%胎牛血清(康宁(Corning)公司,位于美国马里兰州(MD,USA)),100U/ml青霉素(penicillin)(康宁(Corning)公司,位于美国马里兰州(MD,USA))、以及100μg/ml链霉素(streptomycin)(康宁(Corning)公司,位于美国马里兰州(MD,USA))的RPMI-1640(康宁(Corning)公司,位于美国马里兰州(MD,USA)),在37℃的5%CO2培养箱中稳定24小时。
以1×106细胞/孔(cells/well)将各个细胞分装于96孔板中,培养24小时后,将核糖-来那度胺或来那度胺分别处理0.1或1μM,经1小时后,处理聚羟基烷酸酯(PHA)(25μg/ml),6小时后,通过实时聚合酶链反应(Real-time PCR)确认核糖核酸(RNA)表达量,24小时后,通过酶联免疫吸附法(ELISA)确认了炎症相关细胞因子的变化。
使用RNA prep kit(Monarch Total RNA Miniprep Kit,NEB),按照制造商说明分离了核糖核酸(RNA),使用LunaScript RT SuperMix kit(NEB)合成了互补脱氧核糖核酸(cDNA),以下,使用引物对进行了逆转录-聚合酶链反应(RT-PCR)。
表2
实验中使用的产品如逆转录-聚合酶链反应(RT-PCR)cyber-gree n:Universal qPCR Master Mix(M3003),Real-time PCR p late(48well):/>Fast Optical 48-well Reaction Plate(4375816,Applied Biosystems),Real-time PCRsealing film(48wel l):MicroAmpTM 48-well Optical Adhesive Film(4375323,Applied Biosystems),实验按照制造商说明进行。
另一方面,通过离心分离分离细胞培养液后,使用Human TNF alpha uncoated酶联免疫吸附法(ELISA)kit(88-7346-22,Invitrogen),按照制造商说明,分析了TNF-α的蛋白质量。
其结果,如图2g和图2h所示,确认核糖-来那度胺(类型1)在信使核糖核酸(mRNA)和蛋白质水平上发挥了与来那度胺相似或略有改善的炎症抑制效果。
1-8.黄斑变性治疗效果
在作为湿润性老年性黄斑变性(wet AMD)模型的mouse CNV模型中,试图确认病变的治愈功效。
为此,使用C57BL/6(Koatech,Korea),7周龄雄性小鼠,每组5只,经过1周的驯化过程后,使用Ketamine hydrochloride(100mg/kg,I.P.)来使8周龄的小鼠麻醉,将一滴Mydriacyl(tropicamide)眼药滴入右眼使之散瞳。3分钟后,将小鼠平躺在贴在狭缝灯上的支架上,并在右眼上方盖上具有隐形眼镜作用的盖玻片。用狭缝灯照射视神经头部后,通过附着在狭缝灯上的532nm激光设备(Irdiex Oculight Tx,USA)照射视神经头部周围4个激光斑点(200mW,50μm斑点尺寸,100ms持续)。
如上所述,产生脉络膜血管生成病变后,将磷酸盐缓冲溶液(PB S)中溶解核糖-来那度胺的溶液施用于病变。对于玻璃体内给药,0.2μg/ml浓度的1.5μL溶液在激光照射后立即通过33G量针的25μL汉密尔顿注射器进行了1次给药。另一方面,将核糖-来那度胺溶解在磷酸盐缓冲溶液(PBS)中使之浓度为2mg/ml以制备眼药水形式,每天给药4次,通过血管荧光染色确认了7天、14天后功效。
荧光染色使用Heidelberg Spectralis HRA+OCT device(Heidel berg,Germany)设备进行,ketamine hydrochloride(100mg/kg,I.P.)和xylazine(10mg/kg,I.P.)进行麻醉之后,通过对右眼应用一滴Myd riacyl眼药水(tropicamide)来使之散瞳之后,通过fluorescite 10%(A lcon,USA)0.05mL,I.P.给药对血管进行了染色。Fluorescite注入10分钟后,拍摄了荧光图像。
其结果,如图2i所示,可以确认与对照组给药相比,核糖-来那度胺(类型1)的玻璃体内给药组及眼药水给药组都有明显的病变减少的趋势。
实施例2.葡萄糖-来那度胺(Glucose-Lenalidomide)
2-1.合成
将100mg(0.386mmol)来那度胺溶于1.00mL的二甲基甲酰胺(DMF)和1.00mL的乙醇(EtOH)中后,0.50mL的水(H2O)和53.0μL(0.926mmol)乙酸(AcOH)中溶解加入208mg(1.16mmol)葡萄糖(Glucose)。将混合物在60℃下搅拌过夜并减压浓缩。将残留物经C18-SiO2(水100%~甲醇(MeOH)=3:1)柱层析纯化,以合成了葡萄糖-来那度胺(类型1,式Ⅲ,图3a)。
另一方面,在将200mg(0.772mmol)来那度胺和167mg(0.926mmol)葡萄糖(Glucose)溶于2.00mL的二甲基甲酰胺(DMF)和0.500mL的水(H2O)中的溶液中,加入53.0μL(0.926mmol)乙酸(AcOH)和58.2mg(0.926mmol)氰基硼氢化钠(NaBH3CN)。将混合物在65℃下搅拌过夜。加入1N的HCl使混合物的pH成为pH1~2。用5.00mL的水稀释混合物,用5.00mL的二甲基甲酰胺(DMF)洗涤5次。将水层减压浓缩。将残留物经C18-SiO2(水100%~甲醇(MeOH)=1:5)柱层析纯化,以合成了另一种形式的葡萄糖-来那度胺(类型2,式Ⅳ,图3a)。
2-2.水溶性
采用与实施例1-2相同的方法确认了葡萄糖-来那度胺的水溶性。
其结果,如图3b所示,确认来那度胺几乎不溶于蒸馏水(D.W.),反之,两种类型的葡萄糖-来那度胺在蒸馏水(D.W.)中的溶解度为100mg/ml以上(基于USP 23的易溶解的(Freely soluble))。
2-3.CRBN结合能力
采用与实施例1-3相同的方法确认了葡萄糖-来那度胺的CRBN结合能力。
其结果,如图3c所示,确认葡萄糖-来那度胺的CRBN结合能力与来那度胺相比稍微弱或相似的水平。
2-4.肿瘤细胞凋亡效果
采用与实施例1-4相同的方法确认了葡萄糖-来那度胺的肿瘤细胞凋亡效果。
其结果,如图3d所示,确认葡萄糖-来那度胺(类型1)显现出与来那度胺相似程度的使作为人类多发性骨髓瘤细胞系的MM.1S凋亡的效果。
2-5.人类婆罗双树样基因4(SALL4)分解效果
采用与实施例1-6相同的方法确认了葡萄糖-来那度胺的人类婆罗双树样基因4(SALL4)分解效果。
结果确认,如图3e所示,葡萄糖-来那度胺与来那度胺相比,人类婆罗双树样基因4(SALL4)分解效果显著降低,从而降低了致畸形性副作用的可能性。
2-6.黄斑变性治疗效果
对于葡萄糖-来那度胺的黄斑变性治疗效果,使用作为湿润性老年性黄斑变性(wet AMD)模型的mouse CNV模型,通过与实施例1-8相似的方法向玻璃体内给药1次,并确认了治疗效果。
其结果,如图3f所示,通过葡萄糖-来那度胺(类型1)给药,可确认黄斑变性治疗效果。
实施例3.核糖-泊马度胺(Ribose-Pomalidomide)
3-1.合成
将300mg(1.16mmol)的泊马度胺(Pomalidomide)和1.74g(11.6mmol)的核糖(Ribose)、9.00mL的二恶烷(Dioxane)溶于0.75mL的水中,接着加入了53.0μL(0.926mmol)乙酸(AcOH)。将混合物在100℃下搅拌过夜。将残留物用5.0mL的水稀释,用10.0mL的二甲基甲酰胺(DMF)洗涤4次。将水层减压浓缩。将残留物经SiO2(二氯甲烷(DCM):甲醇(MeOH)=9:1)柱层析纯化,以获得可247mg的核糖-泊马度胺(类型1,式Ⅸ,图4a)。
将247mg的核糖-泊马度胺(类型1)溶于4.0mL的水,加入了53.0μL(0.926mmol)乙酸(AcOH)和76.6mg(1.22mmol)的氰基硼氢化钠(NaBH3CN)。将混合物在常温下搅拌4.5小时。加入1N的H Cl,使混合物的pH成为pH1~2。将混合物用5.00mL的二甲基甲酰胺(DMF)洗涤3次。将水层减压浓缩。将残留物经二氧化硅(SiO2)(二氯甲烷(DCM):甲醇(MeOH)=8:2)柱层析纯化后,通过C18-SiO2(水100%~甲醇(MeOH):H2O=1:3~1:1)柱层析纯化。将包含核糖-泊马度胺的分割汇集、浓缩,正己烷(n-hexane)处理,合成了74.2mg的核糖-泊马度胺(类型2,式Ⅹ,图4a)。
3-2.水溶性
采用与实施例1-2相同的方法,确认了两种类型的核糖-泊马度胺的水溶性。
其结果确认,如图4b所示,核糖-泊马度胺(类型1)在0.1mg/ml以下的浓度下也继续沉淀(基于USP23的几乎不溶或不溶(Practically insoluble or Insoluble)水平),核糖-泊马度胺(类型2)在11mg/mL的浓度下溶解,而没有肉眼可见的沉淀(基于USP23的难溶(Sparingly soluble)水平)。
3-3.CRBN结合能力
采用与实施例1-3相同的方法确认了核糖-泊马度胺的CRBN结合能力。
其结果,如图4c所示,两种类型的核糖-泊马度胺显示出与泊马度胺几乎相似或稍微改善的水平的CRBN结合能力。
3-4.肿瘤细胞凋亡效果
使用与实施例1-4相同的方法确认了核糖-泊马度胺的肿瘤细胞凋亡效果。
其结果确认,如图4d所示,通过核糖-泊马度胺(类型1)作为人类多发性骨髓瘤细胞系的MM.1S的生命力(viability)降低,但通过核糖-泊马度胺(类型2),作为人类多发性骨髓瘤细胞系的MM.1S细胞生命力没有显著降低。
3-5.人类婆罗双树样基因4(SALL4)分解效果
采用与实施例1-5相同的方法确认了核糖-泊马度胺的人类婆罗双树样基因4(SALL4)分解效果。
其结果确认,如图4e所示,与泊马度胺相比,核糖-泊马度胺(类型2)的人类婆罗双树样基因4(SALL4)分解效果显著降低,致畸形性副作用的可能性降低。
实施例4.葡萄糖-泊马度胺(Glucose-Pomalidomide)
4-1.合成
将300mg(1.16mmol)的泊马度胺(Pomalidomide)和2.09g(11.6mmol)的葡萄糖(Glucose)、9.00mL的二恶烷(Dioxane)溶于0.75mL的水中后,加入了53.0μL(0.926mmol)乙酸(AcOH)。将混合物在100℃下搅拌过夜并减压浓缩。用10.0mL的水稀释残留物,用10.0mL的二甲基甲酰胺(DMF)洗涤4次。将水层减压浓缩。将残留物经C18-SiO2(水100%~甲醇(MeOH):H2O=3:1)柱层析纯化,以获得了96.8mg的葡萄糖-泊马度胺(类型1,式Ⅶ,图5a)。
将96.8mg的葡萄糖-泊马度胺(类型1)溶于1.5mL的水中,加入了乙酸(AcOH)(3滴)和27.9mg(0.445mmol)的氰基硼氢化钠(N aBH3CN)。将混合物在常温下搅拌了4.5小时。加入1N的HCl,使混合物的pH成为pH1~2。将混合物用3.00mL的二甲基甲酰胺(DMF)洗涤3次。将水层减压浓缩。将残留物经二氧化硅(SiO2)(二氯甲烷(DCM):甲醇(MeOH)=8:2)柱层析纯化。包含葡萄糖-泊马度胺(类型2)的分割汇聚、浓缩,并正己烷(n-hexane)处理,以合成了68.6mg的葡萄糖-泊马度胺(类型2,式VⅢ,图5a)。
4-2.水溶性
采用与实施例1-2相同的方法,确认了葡萄糖-泊马度胺的水溶性。
其结果确认,如图5b所示,两种类型的葡萄糖-泊马度胺的水溶性与泊马度胺相比显著提高。
4-3.CRBN结合能力
采用与实施例1-3相同的方法确认了葡萄糖-泊马度胺的CRBN结合能力。
其结果,如图5c所示,可以确认葡萄糖-泊马度胺的CRBN的结合能力。
4-4.肿瘤细胞凋亡效果
采用与实施例1-4相同的方法,确认了葡萄糖-泊马度胺的肿瘤细胞凋亡效果。
其结果确认,如图5d所示,通过葡萄糖-泊马度胺(类型1),作为人类多发性骨髓瘤细胞系的MM.1S的生命力(viability)降低,但通过葡萄糖-泊马度胺(类型2),作为人类多发性骨髓瘤细胞系的MM.1S细胞生命力没有大幅降低。
以上,详细描述了本发明内容的特定部分,本技术领域所属的普通技术人员清楚的是这些具体描述仅为优选实施方式,本发明的范围不受限于此。因此,本发明的实质范围应由所附发明要求保护范围以及它们的等同物来定义。
Claims (17)
1.一种来那度胺或泊马度胺衍生物,其特征在于,来那度胺或泊马度胺的邻苯二甲酰亚胺部分上的氨基中结合有糖或糖衍生物。
2.根据权利要求1所述的来那度胺或泊马度胺衍生物,其特征在于,所述糖或糖衍生物为三碳糖、四碳糖、五碳糖或六碳糖或其衍生物。
3.根据权利要求1所述的来那度胺或泊马度胺衍生物,其特征在于,所述糖或糖衍生物为葡萄糖(Glucose)、核糖(Ribose)、葡萄糖醛酸(Glucuronic acid)或甘油醛(Glycerinaldehyde)。
4.根据权利要求3所述的来那度胺或泊马度胺衍生物,其特征在于,所述衍生物选自由以下式Ⅲ至式XⅣ组成的组中:
[式Ⅲ]
[式Ⅳ]
[式Ⅴ]
[式Ⅵ]
[式Ⅶ]
[式VⅢ]
[式Ⅸ]
[式X]
[式XI]
[式XⅡ]
[式XⅢ]
以及
[式XⅣ]
5.根据权利要求1所述的来那度胺或泊马度胺衍生物,其特征在于,与来那度胺或泊马度胺相比,所述衍生物的水溶性(water solubility)提高50%以上。
6.一种用于预防或治疗癌症的药物组合物,其特征在于,包含权利要求1至5中任一项所述的衍生物作为有效成分。
7.根据权利要求6所述的组合物,其特征在于,所述癌症为血癌或固体癌症。
8.根据权利要求7所述的组合物,其特征在于,所述血癌选自由急性白血病、慢性白血病、多发性骨髓瘤、霍奇金淋巴瘤及非霍奇金淋巴瘤组成的组中。
9.一种用于预防或治疗骨髓增生异常综合征的药物组合物,其特征在于,包含权利要求1至5中任一项所述的衍生物作为有效成分。
10.一种用于预防或治疗炎症疾病的药物组合物,其特征在于,包含权利要求1至5中任一项所述的衍生物作为有效成分。
11.根据权利要求10所述的组合物,其特征在于,所述炎症疾病选自由牛皮癣、风湿性关节炎及克罗恩病组成的组中。
12.一种用于预防或治疗脑疾病的药物组合物,其特征在于,包含权利要求1至5中任一项所述的衍生物作为有效成分。
13.根据权利要求12所述的组合物,其特征在于,所述脑疾病选自由外伤性脑损伤、阿尔茨海默病、帕金森病、亨廷顿病、肌萎缩侧索硬化症、多系统萎缩症、阿尔茨海默性痴呆症、血管性痴呆症、额颞痴呆症、路易体痴呆、缺血性脑卒中、出血性脑卒中及多发性硬化症组成的组中。
14.一种用于预防或治疗血管生成疾病的药物组合物,其特征在于,包含权利要求1至5中任一项所述的衍生物作为有效成分。
15.根据权利要求14所述的组合物,其特征在于,所述血管生成疾病选自由角膜移植后血管新生、新生血管性青光眼、糖尿病性视网膜病、黄斑变性、糖尿病性黄斑水肿、新生血管引起的角膜疾病、斑点的变性、翼状片、视网膜变性、晶体后纤维增生症、颗粒性结膜炎、血管瘤、血管纤维瘤、血管畸形、动脉硬化、血管粘连及浮肿性硬化症组成的组中。
16.一种注射液制剂,其特征在于,包含权利要求1至5中任一项所述的衍生物。
17.一种滴眼液制剂,其特征在于,包含权利要求1至5中任一项所述的衍生物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0102394 | 2021-08-04 | ||
KR20210102394 | 2021-08-04 | ||
PCT/KR2022/011480 WO2023014082A1 (ko) | 2021-08-04 | 2022-08-03 | 물질 특성이 개선된 면역조절아마이드 유도체 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117794909A true CN117794909A (zh) | 2024-03-29 |
Family
ID=85155882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280054582.4A Pending CN117794909A (zh) | 2021-08-04 | 2022-08-03 | 改进物质特性的免疫调节酰胺衍生物 |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR20230023575A (zh) |
CN (1) | CN117794909A (zh) |
WO (1) | WO2023014082A1 (zh) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011018101A1 (en) * | 2009-08-12 | 2011-02-17 | Synthon B.V. | Lenalidomide salts |
CN103421061A (zh) * | 2013-08-14 | 2013-12-04 | 中国药科大学 | 来那度胺衍生物、其制法及其医药用途 |
RS64038B1 (sr) * | 2014-08-22 | 2023-04-28 | Celgene Corp | Postupci za lečenje multiplog mijeloma imunomodulatornim jedinjenjima u kombinaciji sa antitelima |
KR102072546B1 (ko) | 2016-10-14 | 2020-02-04 | 주식회사 삼양바이오팜 | 레날리도마이드의 경구용 정제 조성물 |
KR20200078498A (ko) * | 2017-10-26 | 2020-07-01 | 신바이어스 파마 아게 | 레날리도마이드 즉시 방출 제형 |
KR102286499B1 (ko) * | 2018-04-13 | 2021-08-05 | 주식회사 삼양홀딩스 | 레날리도마이드를 포함하는 약제학적 조성물 |
-
2022
- 2022-08-03 KR KR1020220096690A patent/KR20230023575A/ko unknown
- 2022-08-03 CN CN202280054582.4A patent/CN117794909A/zh active Pending
- 2022-08-03 WO PCT/KR2022/011480 patent/WO2023014082A1/ko active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2023014082A1 (ko) | 2023-02-09 |
KR20230023575A (ko) | 2023-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11274123B2 (en) | 1,2,4-oxadiazole compounds as inhibitors of CD47 signalling | |
US9776978B2 (en) | 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators | |
US6573292B1 (en) | Methods and compositions for the treatment of chronic lymphocytic leukemia | |
AU2013293646B2 (en) | Organic compounds | |
US5776947A (en) | Use of quinoline-3-carboxamide compounds for inhibiting the production of tumor necrosis factor (TNF) and/or for the treatment of septic shock | |
JP2005538093A (ja) | 抗血管形成療法のための、テトラポリアンモニウムテトラチオモリブデートおよび関連化合物 | |
JP2019515909A (ja) | 慢性リンパ性白血病の治療を目的とするhdac阻害剤単独またはbtk阻害剤との配合物 | |
JP2022507025A (ja) | 小分子cd-47阻害剤の他の抗癌剤との組み合わせ | |
JP2005530786A (ja) | 心損傷の処置のためのピロロキノリンキノンおよびその使用方法 | |
CN117794909A (zh) | 改进物质特性的免疫调节酰胺衍生物 | |
KR20200094110A (ko) | 스트렙토니그린 및 항암제를 포함하는 뇌종양 예방 또는 치료용 조성물 | |
WO2023019244A9 (en) | Compositions and methods for reducing immune intolerance and treating autoimmune disorders | |
JP2007536256A (ja) | 心臓損傷の処置のためのピロロキノリンキノン薬およびその使用方法 | |
EP2637665B1 (en) | Dexamethasone combination therapy | |
KR20240001072A (ko) | 신규한 포말리도마이드 유도체 및 이의 제조방법 | |
JPH0378368B2 (zh) | ||
CN115300507B (zh) | I-brd9作为arih1激动剂的用途 | |
WO2011156900A2 (en) | Compounds, compositions and methods for treatment of multiple sclerosis | |
US6455555B1 (en) | Anti-HIV infection agents and method for treating HIV infection | |
WO2021022258A1 (en) | Tetracycline compounds for the treatment of hematological cancers | |
KR20230128236A (ko) | 신규한 포말리도마이드 유도체의 뇌질환 치료 용도 | |
CN114340672A (zh) | 包含hdac抑制剂和抗pd1抗体或抗pd-l1抗体的药物组合物 | |
CN111419853A (zh) | 一种治疗乳腺癌的葫芦素与依鲁替尼组合物 | |
EA015503B1 (ru) | Применение 4-циклопропилметокси-n-(3,5-дихлор-1-оксидопиридин-4-ил)-5-(метокси)пиридин-2-карбоксамида для лечения черепно-мозговых травм | |
Wechter et al. | Pillsbury Winthrop LLP |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |